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Abstract
U.S. Food and Drug Administration (FDA) recalls of medical devices are at historically
high levels despite efforts by manufacturers to meet stringent agency requirements to
ensure quality and patient safety. A factor in the release of potentially dangerous devices
might be the interpretations of nonnormal test data by statistically unsophisticated
engineers. The purpose of this study was to test the hypothesis that testing by lot provides
a better indicator of true process behavior than process capability indices (PCIs)
calculated from the mixed lots that often occur in a typical production situation. The
foundations of this research were in the prior work of Bertalanffy, Kane, Shewhart, and
Taylor. The research questions examined whether lot traceability allows the
decomposition of the combination distribution to allow more accurate calculations of
PCIs used to monitor medical device production. The study was semiexperimental, using
simulated data. While the simulated data were random, the study was a quasiexperimental
design because of the control of the simulated data through parameter selection. The
results of this study indicate that decomposition does not increase the accuracy of the
PCI. The conclusion is that a systems approach using the PCI, additional statistical tools,
and expert knowledge could yield more accurate results than could decomposition alone.
More accurate results could ensure the production of safer medical devices by correctly
identifying noncapable processes (i.e., processes that may not produce required results),
while also preventing needless waste of resources and delays in potentially life-savings
technology, reaching patients in cases where processes evaluate as noncapable when they
are actually capable.
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Chapter 1: Introduction to the Study
Manufacturing firms in the highly regulated medical device industry rely on
process capability indices (PCIs) to ensure that the processes used to manufacture
products are capable and under control. However, analysis of nonnormal data with a PCI
can result in false indicators. From a management viewpoint, misreading the degree of
control of processes can result in large fines and possibly even felony convictions.
From a social change perspective, this study was important for three specific
reasons. First, correcting a capable process when PCIs give a false reading wastes
resources. This waste of resources needlessly increases the cost of the devices. Second,
along with wasting resources, time spent improving an already capable process could
delay the introduction of potentially life-saving devices to the health community. Third, if
PCIs overestimate the capability of a process, patient wellbeing is at risk. These
conditions represent factors that contribute to the health care system inefficiencies.
This chapter contains the following: (a) the history of PCIs, the Food and Drug
Administration (FDA) regulatory environment, and the important role PCIs fill in the
medical device manufacturing environment; (b) a formal problem statement along with a
description of the method suggested to answer the research questions generated by the
problem statement; and (c) an examination of the significance of this study with regard to
its potential contribution to theory, practice, and positive social change.
Background of the Study
This section contains (a) a very short description of medical device manufacturing
and testing, (b) an account of the function of PCIs including the history of their
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development, (c) a summary of the issues with applying them to everyday problems
involving the analysis of nonnormal data, and (d) an explanation of how the lack of
training in advanced statistical techniques exacerbates the problems with using PCIs. The
section concludes with a description of the development of a tool that could remedy this
situation under some conditions, providing a potentially valuable addition to engineering
methods.
Medical Device Manufacturing
Medical devices, like many other products, are composed of various components,
which themselves may be made up of other components. Figure 1 is an illustration of a
simplified block diagram of a generic device.

Figure 1. Simplified block diagram of a manufactured product.
Performance characteristics of the components used in the manufacture of a
medical device, as well as the finished device itself, must be capable of meeting their
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design requirements. To ensure that this is the case, testing that yields quantifiable results
is the preferred method. There are two approaches to demonstrate that components or
devices meet design requirements (International Organization for Standardization [ISO],
2016).
The first, and preferred method, is to validate the manufacturing process. This is a
procedure that ensures that the process is capable of consistently producing output that
meets specifications. In cases where process validation is not possible, regulatory bodies
require verification of the output, usually through an inspection of the output, which
might include sampling for more intense inspection that can include destructive testing
(ISO, 2016).
The goal is to ensure process output that is capable of consistently meeting the
specifications. A common tool used to monitor process output is the PCI. The primary
motivation for this dissertation was to examine the use of PCIs in the measurement of key
quantifiable test results.
Process Capability Indices
Description. PCIs are statistical tools used to determine if a process can produce
output that consistently meets specifications (Kotz & Johnson, 1993). Intrinsically, the
benefit of keeping a process under control is a simple idea to grasp, but there may be
different reasons beyond the obvious for requiring this condition. First, if an output fails
to meet its desired specifications, it could require rework to become usable, or, in other
cases, scrapped. Both of these situations can have a severe effect on both the cost and
capacity of an operation. The goal of process design is to build a process that can produce
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output correctly, not just the first time, but almost every time. The use of PCIs can be a
valuable tool in determining if this goal is achievable.
A second reason for the use of a PCI is the need to meet customer requirements.
The third reason is, in some cases, manufacturers must demonstrate that processes are
capable of producing their desired output by regulatory agencies (Peña-Rodríguez, 2013).
The FDA has the authority to shut down a noncomplying operation and impose
substantial fines upon, or even to bring criminal charges against, the management of such
activities (Maximum Penalty Amounts, 2014). Another option available to the FDA is to
impose a product recall in the case of products that present a danger to public safety
(FDA, 2017). Such recalls may not only be expensive in terms of the product removed
from user’s inventories, but may also have an effect on a company’s reputation and stock
price. In the worst case, a nonconforming product might result in the injury or death of
patients.
Development. The earliest reference to PCIs in Kotz and Johnson’s (2002)
exhaustive bibliography of references on the topic is the third edition of Juran’s Quality
Handbook published in 1974. This reference would date the use or discussion of this tool
to the period prior to the great wave of interest in Japanese management and statistical
methods that characterize the period beginning in the early nineteen eighties. Juran’s
reference (as cited in Kane, 1986) is to the most basic of the PCIs, Cp, now defined as:
Cp =

USL − LSL
,
6σ

(1)
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where USL and LSL refer to the Upper and Lower Specification Limits respectively, and
σ is the standard deviation of the process. Other authors use UTL and LTL, where the T
refers to tolerance rather than specification (Shewhart, 1931/2015). A normally
distributed process output with a known standard deviation forms the underlying
assumption (Kane, 1986).
Upon the publication of the fourth edition of Juran’s Handbook in 1988, Gryna
(1988) expanded the section on PCIs to include the work of Kane (1986), who explicitly
added Cpk, defined as:

 µ − LSL USL − µ 
C pk = Min
,
.
3σ 
 3σ

(2)

In Equation 2, μ refers to the mean of the process. The equation requires the calculation
of both terms within the braces, and then the selection of the smaller of the two values as
the value of Cpk. For clarification, since Kane’s work, the μ and σ used in the expressions
for Cpk are short-term values.
Equation 2, in terms of CPU and CPL, where Cpk is the minimum of the two,
becomes,
CPL =

µ − LSL
,
3σ

CPU =

USL − µ
,
3σ

C pk = Min{CPL, CPU} .

(3)

(4)
(5)
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The Problems with PCI Use
Many objections to the concept of PCIs began to surface shortly after the
publication of Kane’s work. The literature review section of this dissertation contains a
detailed discussion of these objections, but one of the major objections is the underlying
assumption of normality in the output of a process (Gunter, 1989a). If the output were not
normal, would the users of the PCI be astute enough to recognize that the index was
unusable? Would they recognize the need for further steps before the use of the capability
result?
Hogg (1985) documented that in training programs for SQC, American engineers
lacked the statistical knowledge required to implement these techniques, and
recommended methods to remedy this situation. Ten years later, Kettenring (1995) noted
that this problem still existed. Eighteen years after Kettenring published some statistical
training recommendations, Romeu (2013) verified that the problem defied solution,
noting that engineering curricula are already very full, demanding, and growing.
There is little room for the addition of statistical coursework to curricula in spite
of the need for engineers to learn statistics to take advantage of the latest Six Sigma and
lean methods. Romeu recommended that engineers independently learn more advanced
statistical methods. Sleeper (2007) pointed out that even in statistics-intense training,
such as Six Sigma, engineers do not learn ways of addressing more complex issues.
These complex problems include the analysis of nonnormal data.
Available statistical tools could contribute to this problem. For example, Minitab
is the most commonly used tool in Six Sigma statistical analysis (Brook, 2006). Until the
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advent of Minitab 16 (2010), and its Assistant feature, Minitab output would show
capabilities without indications of possible problems. This calculation occurred
regardless of the underlying distribution, or lack of distribution. The user interpreted the
results without help. With Minitab 16’s Assistant, the software offers automated feedback
on the validity of the results.
If an engineer is fortunate enough to take a statistics course, it may only cover
basic statistics, with the distributions taught commonly being limited to the normal, t, F,
binomial, and chi-squared. When faced with nonnormal data, an engineer, exposed only
to these basic distributions, may not be aware of the techniques for fitting data to more
appropriate distributions. Undergraduate courses generally do not cover other methods
for addressing nonnormality, for example, transformations (Field, 2012).
Given the demands on an engineer’s available time for learning, it may not be
possible to teach the techniques needed to address the calculation and interpretation of
PCIs for all but the simplest, normally distributed data (Romeu, 2013). But, it may be
possible to develop tools to highlight and quantify areas of high risk. These tools could
supplement the Process Failure Mode Effects Analysis (PFMEA) commonly created
during the development of medical products. The goal for this study was to provide one
such tool, addressing a need revealed by a review of the literature.
Problem Statement
Release of unsafe medical devices into the market threatens patient lives and
wellbeing (FDA, 2013; Nagreha & Parmar, 2011). A statistical quality approach offers a
partial solution to this problem (Food and Drug Administration [FDA], 2011; Global
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Harmonization Task Force [GHTF], 2004; ISO, 2016). The most frequently used tool to
measure the output quality of a medical device manufacturing process is the PCI (PeñaRodríguez, 2013). PCIs, as originally proposed by Kane (1986) require normal data.
However, measured data from many processes do not exhibit normality (Sleeper, 2007).
The FDA can impose penalties of over $10 million for violations of the Food and Drug
Act (FDA, 2011a).
No articles written about PCIs specifically focus on their use in the field of
medical manufacturing. A thorough search of the available literature resulted in no
articles that specifically addressed the use of PCIs in medical device manufacturing.
Medical manufacturing, because of the FDA requirement for lot traceability, offers a
unique structure to overcome problems of nonnormality.
Purpose of the Study
The purpose of this empirical quantitative study was to develop a framework that
evaluates the ability of a PCI to accurately measure medical device test data under a
scenario where output data combines the effects of mixed production lots of components.
The study was comparative in nature, involving an examination of the performance of the
most commonly used PCI, Cpk, using simulated process data by calculating precise
capabilities and then comparing these values with the results generated from nonnormal
data adjusted indices. Data in this study consisted of combinations of data from different
distributions to represent the situation where a lot of raw material used in a process
consists of material from several supplier lots. The simulated data represent test values
from some production test and are the independent variables. Using simulated data
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negates the influence of, or need to control for, any independent variables, because only
the final value of a test resulted from the simulation. The value of the calculated PCI was
the dependent variable of interest in this study. Successful completion of this study gives
evidence of the applicability of PCIs to results that may come from the combination of
distributions. The findings could lead to further research that will provide tools that are
more accurate for practice in the future.
Research Questions and Hypotheses
The quantitative research question of this research was how accurately does the
calculated value of Cpk, under the assumption of normality, reflect the actual probabilities
of nonconformance from simulated distributions representing the mixture of components
from different upstream production batches in a subsequent process? This question
reflects the real-world situation in which a production line uses components from several
different lots. A PCI, as used in industry, is primarily a point value (Porter & Oakland,
1991). A quality manual or protocol may state that the Cpk value must be greater than
1.33, 1.50, or some other value. This question leads to three formal research questions.
The first series of tests involve the comparison of calculated values of the PCIs
based on samples taken from each distribution set to a required value.
Research Question 1: Do the PCIs calculated from samples of the combined
distributions meet the industry standard?
H01: PCIC ≥ 1.33,
Ha1: PCIC < 1.33.
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Peña-Rodríguez (2013) suggested the value 1.33. PCIC will be the Cpk calculated
using sample sizes at levels of 10, 30, 59, and a value determined from each of the 12
distributions using the method described by Mathews (2010). The data in all research
questions represents the test results from a test conducted after the assembly of the tested
component from parts from different lots. The test addressed both raw and normally
transformed data.
The second series of tests involve a comparison of the calculated positions on the
x-axis of 4 standard deviations, equivalent to a Cpk of 1.33 to the value calculated from
the parameters of the 12 combined distributions and their transformed values.
Research Question 2: Do the values calculated from samples taken from a
combined distribution exceed the actual values required to meet the industry standard?
H02: xpci ≥ xpdf,
Ha2: xpci < xpdf.
xpci is the x-axis value calculated from the required value of the PCI, and xpdf is the
value calculated directly from the combined probability density functions. The results of
this test should mirror those of Research Question 1, but shows the percentage difference
between the actual and calculated values. The tests addressed both raw and transformed
data. Previous tests have used the combined distributions. The third series of tests
involved testing the components of the combined distributions individually and
comparing the PCI calculated from these distributions with the standard Cpk of 1.33.
Research Question 3: Do the data values from the lateral distributions, isolated
from the underlying normal distributions, meet the industry standard?
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H03: PCgamma ≥ 1.33,
Ha3: PCgamma < 1.33,
H03: PClognormal ≥ 1.33,
Ha3: PClognormal < 1.33,
H03: PCWeibull ≥ 1.33,
Ha3: PCWeibull < 1.33.
In these hypotheses, PCgamma is the Cpk calculated from the gamma distributions,
PClognormal is the Cpk calculated from the lognormal distributions, and PCWeibull is the Cpk
calculated from the Weibull distributions. These tests evaluate the suggestion that lots
constructed using different lots of components require individual tests. This individual
testing might compensate for the effect of a fattened tail on the value of the standard
deviation used to calculate the capability index. Testing addressed both raw and
transformed data.
The operationalization of the above RQ into a null and alternative hypothesis
required the calculation of the PCIs from sample sizes of 10, 30, 59, and a sample size
needed to achieve an a priori specified power 1 - beta. The value of 10 represents a low
convenience value. A sample size of 30 represents the situation where statistics students
correctly learn that this is the number at which a t distribution approximates a normal
distribution and use it as a default sample size. The sample size of 59 achieves a 95%
level of confidence and a 95% reliability level (Lipson & Sheth, 1973). The calculated
sample size based on power was indeterminate until the generation of simulated results as
described in the next chapter.

12
Tests on the variance/standard deviation and the chi-square distributions
determined the outcome of the hypothesis testing. This testing examined if a Type II error
was occurring in the calculation of the PCI by using the definitional equation for Cpk to
calculate the values for the sample PCIs. The probabilities as defined by the generating
cumulative distribution functions yielded the actual values of the indices. From the
definitional equation for Cpk, it was readily apparent that the value of the index is directly
proportional to the distance between the mean of the samples and the specification limit,
and inversely proportional to the standard deviation of the sample. This establishes cause
and effect of the data on the value of the PCI.
Theoretical Foundation
The theoretical mathematical underpinnings of this dissertation begin with the
work of the famous astronomer Newcomb (1886), who hypothesized that data from
combinations of several distributions can compose the observations of natural
phenomena. In actuality, the data was from just one distribution. Newcomb was
examining the effect of errors that occurred during the observation of astronomical
phenomena. Thus, the data from an astronomical observation of a celestial body from
three different observatories, or using three different instruments, might appear to come
from three different normal distributions. In reality, they came from just one. Of
particular concern was the identification and elimination of outliers because of their
contribution to this effect.
A review of the literature suggested that this concept remained dormant until
Tukey (1960) reintroduced it. Rather than examining normal distributions with different
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means and standard deviations, Tukey looked at a combination of two normal
distributions with the same mean and different standard deviations. The sample data
drawn from the two distributions has a probability of ε that it comes from one
distribution, and of (1 – ε) that it comes from the other.
Tukey’s (1960) concept of the contaminated or mixed normal distribution often
serves as the introductory idea in the literature addressing the topic of modern or robust
statistics. For example, Wilcox (2012, p.2) expressed it as,

x
H ( x) = (1 − ε )Φ( x) + ε Φ   ,
K

(6)

where K is a constant greater than zero. As Wilcox indicated, it is possible to determine
the parameters of the distribution in Equation 6.
Using the foundation of a contaminated or mixed distribution, the next step
examined the effect of mixing three distributions that are not necessarily normal and then
consider the impact that such a combination may have on the calculation of Cpk. The
expectation was that a mixture of data from different distributions may give misleading
results, even if data taken individually from each distribution provided satisfactory index
values. Overstatement of index values may produce a risk to patient safety; if
understated, a waste of resources could result from fixing a process that is performing
adequately. Such a waste of resources needlessly contributes to the increase in the cost of
medical devices. A delay wastes time correcting an already capable process. This could
result in a postponement in the introduction of possibly life-saving devices to medical
practitioners.
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The management framework for this study combined principles of scientific
management, statistics applied to quality control, and systems theory; it rested on the
work of three scholars. The first, Taylor (1911/1998), applied the principles of scientific
management to work by measuring output and setting standards. The second, Shewhart
(1931/2015), applied statistical techniques to the problem of production quality. The last,
von Bertalanffy (1969), first formulated the systems approach.
To protect the public from the potentially hazardous effects of poorly
manufactured medical devices, the FDA (2009) combined the measurement approach
pioneered by Taylor with the statistical analysis quality techniques first advanced by
Shewhart to develop a system to evaluate the output of a production activity for the
manufacture of medical devices. The FDA system relies on an extension to Shewhart’s
earlier work by Kane (1986) and requires the calculation of a PCI, generally Cpk, to
evaluate the output of a process. In cases of nonnormality of data, the accuracy of this
index can deteriorate leading to either an overestimation or an underestimation of the
quality of the process output (Gunter, 1989a, 1989b, 1989c, 1989d). Neither situation is
desirable.
Nature of the Study
This study involved the use of simulated data generated from specific
distributions using the R (2016) statistics application. This entailed combining the data
from different distributions, calculating Cpk for each combination of distributions, and
comparing these to the real results. It was possible to calculate accurate values of the
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probabilities of nonconformance because of the known distributions used to generate the
data.
The use of real-world data was impractical for this study. Such real-world data
could take two forms: (a) data specifically generated for this study, and (b) existing data
available from my work as an engineer in the medical device field. In either case, because
of the focus on nonnormal data, the actual character of the PCIs that would describe the
process is indeterminate because the nature of the underlying distribution(s) is unknown.
In the case of extant data, I inquired and was told permission to use it would be
impossible to obtain because of the possibility of any future litigation with the data as
evidence. Using simulated data was a strength, not a shortcoming, because it allowed
more precise control over the data generated for analysis.
The literature reveals a mix of both real-world and simulated data used in the
study of PCI behavior. Pearn and Chen (1997) used real data from the manufacture of
electrolytic capacitors. Pearn, Wu, and Wang (2005) did the same with an application
toward audio speaker production. Niavarani, Noorossana, and Abbasi (2012), Ye, Ma,
and Wang (2011), and several others used simulated data. In a practitioner-oriented book
emphasizing curve fitting, Bothe (2001) focused on the use of real-world data. Simulation
appears to be the preferred method in articles that study the performance of different
indices under varying conditions. Strongly mathematically oriented research often
focuses on results derived solely from the mathematics rather than testing the derived
expressions on any real-world data (University of Bristol, School of Mathematics,
Institute of Pure Mathematics, 2017).
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Another advantage of using simulated data is the control of independent variables.
In this study, the result, Cpk, was the dependent variable. A simulation generated data,
representing test results, to calculate the value of this PCI, and the dispersion of these
values reflects this effect of the independent variables. For example, consider a wire
assembly that has a solder joint on one end, and a crimped connection on the other. After
making a batch of cables, a sample is pull tested to ensure that it meets a minimum
specification. Independent variables, in this case, might include measurement error,
differing operator techniques, various settings on crimp machines, and a range of raw
materials, among others. The net result of the effects of all of these independent variables
is the difference in the values of the pull testing that exists between the different samples.
Simulation of this cable testing would give one result, the ultimate value of the pull test.
Definitions
Terms used in this dissertation are:
Acceptable quality level (AQL): “A specified quality level for each lot such that
the sampling plan will accept a stated percentage (say 95 percent) of submitted lots
having this quality level” (Juran & Gryna, 1974, p. 25.5).
Industry standard: “An established standard, norm, or requirement in a particular
area of business” (Industry standard, n.d.). For Cpk the de facto standard is 1.33 (PeñaRodríguez, 2013).
Installation qualification (IQ): “Establishing documented evidence that process
equipment and ancillary systems are capable of consistently operating within established
limits and tolerances” (FDA, 1996, p. 4-2).
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Operational qualification (OQ): The validation step in which “process parameters
should be challenged to assure that they will result in a product that meets all defined
requirements under all anticipated conditions of manufacturing, i.e., worst case testing”
(GHTF, 2004, p. 10).
Process capability index (PCI): A statistical index developed to “establish the
relationships between the actual process performance and the manufacturing
specifications” (Pearn & Kotz, 2006, p. 7).
Process performance qualification: “Establishing documented evidence that the
process is effective and reproducible” (FDA, 1996, p. 4-2). PQ, for Performance
Qualification, is the common term for this qualification.
Product performance qualification (PPQ): “Establishing documented evidence
through appropriate testing that the finished product produced by a specified process(es)
meets all release requirements for functionality and safety” (FDA, 1996, p. 4-2).
Quality: “Fitness for use” (Montgomery, 2013, p. 6).
Tolerance (or specification) limits: “Set by engineering design function to define
the minimum and maximum values allowable for the product to work properly” (Pearn &
Kotz, 2006, p. 4). Lower limits are often abbreviated LSL or LTL, and upper limits as
USL or UTL.
Validation: “Confirmation by examination and provision of objective evidence of
consistent fulfillment of a particular requirement for a specific intended use can be
consistently fulfilled” (FDA, 1996, p. 4-2).
Target (T): The value of the perfect output from a process as set by engineering.
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Assumptions
An assumption in this study was that process output is often nonnormal in nature.
My experience and the voluminous literature addressing analytical techniques for
nonnormal data were the basis for this assumption. Articles regarding the calculation of
PCIs, when the data may be nonnormal, are just a small subset of the literature
surrounding nonnormality.
While the data from a process may be nonnormal, one assumes that the
practitioner has examined the process to remove all controllable sources of variation
within it. An engineer should not look at the output from a process using a PCI, find that
it is not normal and move on. Nonnormal, or uncontrollable output, is a serious source of
concern. Examining a process using a PCI is an iterative process, and only after executing
all reasonable efforts to bring a process to normality should practitioners accept
nonnormal output (Sleeper, 2007).
The assumption that normality is the desired output from a process was a basis for
this study. In some cases, for example, reliability studies where the Weibull distribution
is the expected output, this may not be true. In these cases, other methods for measuring
process capability are appropriate (Dodson, 2006; Tobias & Trindade, 2012).
Another assumption was that Cpk is often used to measure process capability
output in spite of nonnormality. Cpk is the one most frequently used PCIs because it has
become the de facto standard to measure process capability (Peña-Rodríguez, 2013).
A last assumption was that the specification limits set by the engineer are
appropriate. For example, engineering drawings often contain a block titled Tolerances
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Unless Otherwise Specified (French & Vierck, 1972). If designers are relying on these
block tolerances, they may not reflect the dimensions required to be consistent with the
design requirements. Similarly, other process outputs may not have correct tolerances. In
the literature reviewed for this study, Mathews (2010) was alone in pointing out the need
for accurate specification limits as described above.
Scope and Delimitations
The scope of this study was the evaluation of the PCI Cpk when applied to data
that is nonnormal because it was composed of data from two nonnormal distributions
combined with data generated from a central normal distribution. The data composing the
distribution should be identifiable by the source distribution representing the ability to do
this data decomposition by lot identifier in a practical application of the method.
Distributions used for simulated data generation are the normal, Weibull, lognormal, and
gamma. The normal component is always the central distribution and the nonnormal
distribution data provides the lateral distributions intended to fatten the tails of the
combined distribution. The scope reflects the use of these distributions in simulation
studies found in the literature. Transformation methods used are the Box-Cox, square
root, inverse, inverse square root, and asinh (Rivera, Hubele, & Lawrence, 1995).
The scope of this study was only testing that generates quantitative data of the
measurement of some component characteristic, for example, length or breaking force. It
does not apply to a process that relies on qualitative judgments of product quality. The
proposed method would not be applicable to measuring the aesthetics of surface finish
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unless there is also quantitative definition. “Scratches after finishing can be no more than
0.001 inches deep,” is such a definition.
Additionally, the study scope only includes processes where components are
identifiable and separated by lot or job number. Components mixed without identification
before a downstream process would make the tool developed and evaluated in this study
inapplicable.
The scope of this study does not include PCIs based on any other techniques than
comparing the number of standard deviations from the closest specification limit. For
example, it does not include methods based on yield (Grau, 2011, 2012). Because this
study is mathematical in nature, it should be generalizable to any process that produces
measurable output similar to that of the output of the simulation.
Limitations
This study was a quantitative statistical exercise and did not involve the use of a
questionnaire, a survey instrument of any kind, or existing data. No coding of results was
necessary; thus, there was no dependence on the training or judgment of coders. The
numeric values of the results, rather than the opinion of the experimenter, classified them
as conforming or nonconforming. The classification as conforming or nonconforming
depends on the output of the definitional equation for Cpk. Definitional equations are
inherently externally and internally valid. Definitional equations will give incorrect
results when applied improperly, but the results will be consistent with the mathematical
method used in the formulation of the equation.
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As shown by their formulas, there are an infinite number of frequency
distributions. For example, the standard normal distribution has a mean of zero and a
standard deviation of one. An experimenter could not list all of the normal distributions
with a standard deviation greater than zero and less than or equal to one. It would be
impossible to do so because there are an infinite number of values between these two
limits; mathematically, it is an uncountable set. Selecting particular parametric
distributions, with specific parameter values, limited the output from this study to
combinations of distributions that are close enough for the results to be applicable.
A possible limitation of the study arose from the decision to distribute the lateral
distributions symmetrically around the mean of the underlying normal distribution. This
may have been responsible for the low number of failures with the application of the
Anderson Darling test to the combination distributions. This finding is a possible topic
for further research and discussed further in Chapter 5.
The R random number generator in the R (2016) statistics program generated the
values used in this study. From the total data generated, I drew samples using the R
sample function. This tool eliminated any bias in sample selection.
Significance of the Study
This section contains a discussion of the significance of this study with respect to
theory, practice, and social change. From a theory viewpoint, the results of this study may
extend the application of PCIs specifically to the medical manufacturing field. For
practitioners, this study provides another tool that engineers in regulated industries can
apply in addressing nonnormal data. Finally, from a social change prospective, the
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application of the findings of this study could possibly reduce the cost of medical
devices, reduce time to market for some devices, and help prevent dangerous devices
from reaching the market.
Significance to Theory
Looking at the early development of PCIs, it is impossible to find any significant
theoretical breakthroughs from their development and use. Rather, they are a repackaging
of existing statistical tools that give a more easily understood result. They are tools used
to judge if a process can be depended on to produce consistent output that conforms to
the desired specifications. These specifications themselves are engineering constructs of
some characteristic of the part or assembly indicating the bounds within which it is
suitable for use (Kane, 1986).
In the case of a finished device, for example, a pacemaker, an engineer possibly
can use PCIs to evaluate if that device will furnish signals at the correct time and with the
proper amplitude and frequency. In the case of a locating pin, they may indicate if the
parts produced by a process will consistently fit into a mating hole. An evaluation of the
risk that arises from the requirement that the output of a process must meet a particular
value of Cpk. was a primary goal for this study. The focus was on the medical device
field. Peña-Rodríguez’s (2013) value guidelines are the standard of comparison.
After an initial flurry of activity over the first few decades following their
introduction, the study of PCIs appears to have slowed. There is a dearth of recent
literature. If the results of this study indicate excessive risk, it is possible that it could
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spur the development or adaptation of more suitable measures of the reliability of process
output.
Significance to Practice
When manufacturing medical products, it is essential that the completed product
will do no harm to a patient. To accomplish this goal, a production line for a new product
undergoes several validation steps. Validation is also required for product line relocations
(FDA, 1996).
The first of these is the Installation Qualification (IQ), which establishes the
ability of the equipment used in production to safely function within the operating
parameters of the process. The second step is the Operational Qualification (OQ), which
establishes the ability of the process to produce acceptable product under all anticipated
operational conditions. The Performance Qualification (PQ) is the third step. This
validation step verifies the ability of the process to produce acceptable product under
normal operating conditions. It is during this validation activity that the engineer uses a
PCI to evaluate production output (FDA, 1996).
A more accurate method of evaluating the output of a process will allow
manufacturing, process, and quality engineers to avoid two different mistakes. From the
mathematics, if a PCI gives a value that is lower than the real value, fixing a process that
is already producing acceptable product may waste time. If a PCI gives a value higher
than the real value, the result may be a compromise of patient safety.
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Significance to Social Change
There are many reasons why the cost of medical care is increasing. One may be
the incorporation of high technology into devices that can routinely perform procedures
that would have been unimaginable only a few decades ago. As these devices become
increasingly complex, more potential failure modes may be possible. Production lines
that may exceed the devices themselves in their level of complexity manufacture these
products.
The output from the production lines must meet the requirements of the next user
in the supply chain (Montgomery, 2013). This condition is true whether the output is just
a component for the next process step or is the finished device ready for patient use. PCIs
are the tool the medical industry relies on to ensure this readiness for the next step (PeñaRodríguez, 2013).
The application of PCIs to data unsuitable for analysis by this family of tools can
have several outcomes depending on the application framework. It is possible that an
accurate quantification of the process capability will result in spite of the unsuitable data.
However, two other outcomes are more likely, either the PCI will indicate that the
method is more capable or less capable than it is. The examination of these assertions was
a goal of this study.
In the first case, the result might be a line shutdown when unusable parts move to
the next process step. An alternative would be that inadvertently using nonconforming
parts might cause field failures, possibly in an operating room. The results from this
scenario could range from an inconvenienced medical team to a dead patient. In the
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second case, the PCI would indicate that the parts from the process are not meeting
specification. In this case, there may be a waste of engineering and manufacturing
resources fixing a problem that does not exist. In addition, there could be a delay in
potentially life-saving devices reaching practitioners while an already capable process is
refined.
In either case, there is a cost to society. This cost is either in the quality of, or in
the addition of more costs to, already expensive goods and services. This study has the
potential to contribute to a remedy for both of these situations, and that could be a
contribution to positive social change.
Summary
This chapter contains an explanation of the early development of PCIs, and their
rise in importance as American industry implemented and expanded SQC methodologies.
Firms implemented SQC to compete with foreign goods thought by the public as having
better quality than their domestic equivalents. The chapter also includes an explanation of
the widespread requirement for the use of these indices in medical device manufacturing
by both domestic and international regulatory agencies.
Also described are some of the shortcomings of PCIs, for example, their reliance
on normality and in-control processes, as well as the lack of sufficient statistical training
on the part of most engineers to overcome these shortcomings. The chapter concludes
with a description of the significance of the research question from theoretical, practical,
and social change perspectives, and proposed a method to answer it.
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The focus of this study came from working as an engineer in the medical device
field. The specific idea arose from the difficulties encountered using capability indices to
validate processes to meet both customer and regulatory agency requirements. The next
chapter contains a discussion of the literature reviewed in an attempt to find a solution to
this problem.
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Chapter 2: Literature Review
In spite of the best efforts of the FDA, ISO, and GHTF to guide the production of
medical devices, large numbers of FDA Class I recalls still occur. Class I recalls occur
when a shortcoming represents a serious threat to the wellbeing or even the life of a
patient. One hundred and nineteen Class I recalls in the period ranging from 2008 to mid2011 were detailed by Nagreha and Parmar (2011). The FDA (2013) reported 307 Class I
recalls during the years 2003 to 2013. These numbers indicate there is some failure
occurring that exposes many patients to such serious risk.
The chapter begins with a review of literature relevant to the development and use
of PCIs, their limitations, required data adjustments needed before their application, and
examples of their use in both real-world and simulated data. Next, is a discussion of the
theoretical foundations of PCIs, as they evolved from the application of statistical
methodology to monitor the state of a production process in the next section. A person
examining the origins of PCIs may link them to SQC and the design of experiments.
The following section includes a review of the literature to determine the ability
of the most significant indices to provide a consistent level of process control. The focus
was on those occasions when the input to the process may vary. The intent of the
regulation of medical devices is to ensure patient treatment with a device that works
consistently and safely. The question was: can PCIs as currently used contribute to this
goal?
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Literature Search Strategy
The use of PCIs is relatively recent. A definition of Cp appeared in the third
edition of Juran’s Quality Control Handbook in 1974. It was the publication of Kane’s
(1986) article that aroused the interest of researchers. Not many books were found for
this review that specifically deal with process capability as opposed to books that
discussed process capability as part of a broader quality perspective or as chapters in
quality handbooks.
Of the books found, three—Bothe (2001) and Wheeler (2000a, 2000b)—were
practitioner-oriented. The focus of these books was on practical applications of indices to
real-world situations. Their subject was existing indices, rather than an extension of basic
applications of statistical methods to process capability studies through the development
of new indices. Wheeler’s books contain no reference section, in contrast to Bothe’s
book, which does.
Kotz and Johnson (1993), Kotz and Lovelace (1998), and Pearn and Kotz (2006)
wrote books that might be of more interest to researchers. The authors of these books
traced the mathematical evolution of many PCIs, from the most general to very
specialized indices, and detailed their strengths and weaknesses. These books contained
extensive bibliographies.
A book that falls between these two categories was Sleeper’s (2007) book. The
purpose of this book was to acquaint the advanced practitioner with some less wellknown frequency distributions. These distributions might arise in the application of Six
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Sigma methodology to real-world problems. This application of Six Sigma methodology
included the use of PCIs in non-normal data situations.
Kotz et al. (2002), Spiring, Leung, Cheng, and Yeung (2003), and Yum and Kim
(2011) wrote three exhaustive bibliographies of the literature of PCIs. The authors list of
Kotz et al. (2002) contains the names of many of the most prominent researchers in the
field. The bibliographies formed the starting point for this literature review providing for
the identification of articles relevant to the research topic, input into Google Scholar’s
Cited by feature to locate more recent articles published since the bibliographies. Also,
many publishers’ journal repositories also offer a Cited by feature.
Process capability has not been an active area of doctoral level research. Kotz et
al. (2002) identified only two doctoral dissertations. Spiring et al. (2003) found six. My
search efforts included ProQuest Dissertations & Theses Global to find more
dissertations. Other databases searched for articles were ABI/Inform Complete,
Academic Search Complete, Business Source Complete, Current Index to Statistics,
Emerald Management, ERIC, MEDLINE, SAGE, and Science Direct.
Because this is a relatively new area of research, the search input did not include a
date range for the search. Search terms included ab(process capability), (ab(process
capability) AND ab((index OR indices)) AND ab((nonnormal OR non-normal))),
(ab(process capability) AND ab((index OR indices)) AND ab((nonnormal OR nonnormal))) AND adv(Kotz, Samuel), (ab(process capability) AND ab((index OR indices))
AND ab((nonnormal OR non-normal))) AND adv("Johnson, Norman L"), ab(process
capability) AND ab((index OR indices)) AND ab((contaminated OR nonnormal)) AND
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ab((contaminated OR non-normal)), and ab(process capability) AND ab((index OR
indices)) AND ab((nonnormal OR non-normal))
Of these, ab(process capability) AND ab((index OR indices)) AND
ab((nonnormal OR non-normal)), gave the best results for dissertations, returning six.
The search yielded 13 dissertations from all sources for review.
The structure of the publication of the articles reviewed appears to follow a
cluster rather than a tree structure. In other research areas with tree structures, Article A
appears, and Article B will come next, building on Article A. B will generate C; C will
inspire D, and so on. In the process capability literature, two articles, in particular, Kane
(1986) and Pearn, Kotz, and Johnson (1992) appeared to be at the center of the cluster.
These two articles generated articles developing a particular application extension, but
this extension will not be very long. Observation of this pattern during this review
showed that new articles will go back to the center of the cluster and start anew.
Depending on the area of research, authors may write new articles adding to the group.
Because of the limited evolutionary nature of this structure, it appears that early articles
are much more relevant to current thinking than might be the case in other areas of
research.
Theoretical Foundation
PCIs are evaluation tools based on the application of statistical methodology
forming the principles of SQC. SQC is the application of specialized statistical methods
to evaluate product quality. Results of the application of SQC guide the adjustment of the
process to achieve quality standards. Continual monitoring can control that process to
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ensure that production of quality products will continue in the future. Shewhart’s
(1931/2015, 1939/1986) research provided the foundation and Deming (1950/1966),
Juran (1988), and Ott (2000) built on this. The Six Sigma approach, as developed by
General Electric, includes several of the tools defined by these authors and many new
ones (Pyzdek, 2003).
In applications of SQC, two questions immediately arise. First, is the process
capable (Grant & Leavenworth, 1980)? Answering this question requires two very
different measures. The designer of the entity defines the first, the specification limit. For
example, if a locating pin is to slide into a hole in a part, then the tolerances, as expressed
by the specification limits, on both diameters must allow the parts to mate. The more
precise the fit required, the tighter the tolerances on both parts (French & Vierck, 1972).
Consider the production of a locating pin. There will be a USL specifying the
maximum diameter, and an LSL defining the minimum diameter. This difference between
the two is the tolerance spread, expressed mathematically as USL - LSL. A process
produces the pin. This manufacturing process will produce parts with some variation
around the target diameter. The range of the variation around the desired dimension is the
natural tolerance of the process. In a capable process, the natural tolerance, expressed as
the distance between three σ above and three σ below the mean value of the parts
produced by the process, will fit within the tolerance spread. The mean of the process
merely serves as a point defining the center of a six-standard deviation interval (Grant &
Leavenworth, 1980).
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For example, the target diameter of the pin may be 0.250 inches. The process may
produce pins with a mean of 0.250 inches and a standard deviation of 0.007 inches. Then
the natural tolerance of the process would stretch from {[0.250 + 3(0.007)] - [0.250 3(0.007)]} inches = 0.042 inches, or 6σ.
Capability does not imply control. Capable refers to the process spread while
control refers to process location. If the target diameter of the pin was 0.3125 ± 0.025
inches [(0.042 < 0.050 = 2(0.025)], the process would still be capable. The process is not
in control because it is producing pins with a diameter of 0.250. The specification is
0.3125. The natural spread of the process is tight enough to fit within the specifications.
For a process to be in control, the natural spread around the mean must fit within the
tolerance spread centered approximately on the target dimension. Good process design
allows the production of acceptable parts within the specification limits. Engineering
specifies these limits on a process whose outputs are going to fall in a natural spread.
This spread happens independently of the engineer’s desired outcome (Montgomery,
2013). This discussion does assume a normal distribution around the process mean.
The difference between capability and control may be subtle but is important.
Figure 2 is an illustration of the various cases possible and is typical of those found in
SQC textbooks to illustrate these concepts, for example, Grant and Leavenworth (1980).
PCIs are the tools used by practitioners to determine how consistently a process can
produce quality parts because they can look at both capability and control.
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Figure 2. Examples of control and capability for different processes.
Panel a is an illustration of a process that is not capable and not in control. The
natural spread would not fit within the tolerance limits. The centering of the process
moved the spread of the process further outside these limits.
In panel b, the mean of the normal process shown is eight, and the standard
deviation is 1.5. The USL is 11, and the LSL is five. Consequently, four standard
deviations lie between the specification limits. This range means that 9.121% of the parts
will lie to the right of the USL, and another 9.121% will lie to the left of the LSL.
If the data in panel b represents process output, it would have a Cp of 0.667.
Because the process mean is at the midpoint between the USL and LSL, CPU and CPL
are both equal to 0.667, which is the same as the value of Cp. Because CPU and CPL are
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equal, Cpk is also equal to 0.667. If the mean of this process was 8.5, and everything else
remained the same, Cp would remain at 0.667 because it is not sensitive to location.
However, CPU would decrease to 0.556 while CPL would increase to 0.778. Because Cpk
is the minimum of CPU and CPL, it would drop from 0.667 to 0.556. The proportion of
parts below the LSL would drop to 5.99% while the percentage of parts above the USL
would increase to 13.33%.
Panel c is data from a process that is capable. The natural spread of the process is
less than the tolerance spread. The location of the process mean moves the output of the
process outside of the tolerance spread.
In Panel d, eight is still the process mean, but the standard deviation is 0.500. In
this case, the Cp and Cpk would be two, and a tiny percentage of parts, less than 0.003%,
would lie outside the specification limits. With a shift in the mean to 8.5, Cp would
remain at two, CPU would decrease to 1.667, and CPL would increase to 2.333. This
increase would result in a Cpk of 1.667. Parts to the left of the LSL would decrease to
0.0002%, and parts to the right of the USL would increase to 0.043%. This example and
the previous one, show that PCIs use the same statistical theory as SQC.
Another theoretical foundation of PCIs is the pioneering work of Fisher in
applying an experimental approach to the study of crop yields (Fisher, 1935/1971).
Fisher’s daughter (Box, 1980, 1987) wrote descriptions of Fisher and Gosset’s early work
in experimental design. The first of these articles is mathematical, the second is
anecdotal.
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Fisher’s (1935/1971) work evolved into a methodology known as the design of
experiments (DOE). Box and others (Box & Draper, 1969; Box, Hunter, & Hunter, 1978)
contributed to the method. Taguchi (1987) further expanded the methodology by
factoring the cost of quality into the DOE methodology. New PCIs incorporated
Taguchi’s concepts of the cost of poor quality (Boyles, 1991).
DOE has evolved into a complex area of study incorporating a wide variety of
methods to optimize performance (Lawson, 2014; Montgomery, 2001). In simple terms,
DOE is a method for structuring experiments, varying parameters, and linking the
changes in the output of the experiment to the changes in the parameters. The FDA has
issued a nonbinding recommendation for DOE use in the determination of process
parameters (FDA, 2011b; Pluta, 2014).
Literature Review
Regulation of Medical Device Manufacturing
Essential to best practices in the manufacture of medical devices is adherence to
multiple regulations from different agencies. These regulations are cited here as literature
because they provide the basis of the need for the research conducted in this study.
Violation of these regulations can result in fines and/or imprisonment of those
responsible for the nonconformance (FDA, 2014).
Advances in medical technology have conquered once devastating diseases and
increased life expectancy in much of the world. However, even in cases where a complex
device functions properly, the failure of a minor subsystem can have potentially
disastrous consequences. Even the failure of a system unrelated to the functioning of the
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device, the sealing of the lid to the tray containing the assembly, can expose patients to
dangerous contamination (Mays, 2008).
Because of the importance of patient safety, medical device manufacturing is a
very highly regulated industry in the United States and abroad. In the United States, the
primary regulatory agency is the U.S. Department of Health and Human Services, Food
and Drug Administration (FDA). Other countries have similar agencies, and the
International Organization for Standardization (ISO, 2016) has issued a standard, ISO
13485, to set requirements for device manufacturing. The Global Harmonization Task
Force (GHTF) had as its mission creating uniform device regulation worldwide. The
International Medical Device Regulators Forum (IMDRF) replaced the GHTF, and issued
guidance documents to accomplish the original task. The activities of these agencies also
include the procedures for the approval of new medical devices. Relevant to this study
are the manufacturing validation procedures that must occur, and the statistical tools used
during these activities. The intent of these analytical tools is to ensure proper and reliable
manufacture of devices.
The FDA provides no specific guidelines on the procedures to follow to ensure a
process is under control. The FDA offers general guidance in Quality System (QS)
Regulation/Medical Device Good Manufacturing Practices, 21CFR820.75 (2013). This
guidance indicates that a process must be under control under specific circumstances,
Subpart G--Production and Process Controls
Sec. 820.75 Process validation.
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(a) Where the results of a process cannot be fully verified by subsequent
inspection and test, the process shall be validated with a high degree of assurance
and approved according to established procedures. The validation activities and
results, including the date and signature of the individual(s) approving the
validation, and, where appropriate, the major equipment validated, shall be
documented.
(b) Each manufacturer shall establish and maintain procedures for monitoring and
control of process parameters for validated processes to ensure that the specified
requirements continue to be met. (p. 151-2)
ISO 13485, Medical devices -- Quality management systems -- Requirements for
regulatory purposes (2016), offers similar guidance,
7.5.6 Validation of processes for production and service provision
The organization shall validate any processes for production and service provision
where the resulting output cannot be or is not verified by subsequent monitoring
or measurement and, as a consequence, deficiencies become apparent only after
the product is in use or the service has been delivered.
Validation shall demonstrate the ability of these processes to achieve planned
results consistently. (p. 19)
In its final report, the recommendations of the GHTF (2003) are similar,
Each process should have a specification describing both the process parameters
and the output desired. The manufacturer should consider whether the output
could be verified by subsequent monitoring or measurement (A). If the answer is
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positive, then the consideration should be made as to whether or not verification
alone is sufficient to eliminate unacceptable risk and is a cost-effective
solution (B). If yes, the output should be verified, and the process should be
appropriately controlled (C).
If the output of the process is not verifiable then the decision should be to validate
the process (D); alternatively, it may become apparent that the product or process
should be redesigned to reduce variation and improve the product or process (E).
In addition, a change in a manufacturing process may result in the need for
process validation even though the process formerly only required verification
and control. (p.7)
PCIs have become the standard to verify process control. Specifically writing
about FDA regulations, Peña-Rodríguez (2013) indicated that a Cpk of 1.33 evidences an
in-control process. An examination of available medical device manufacturer quality
manuals verified this finding. However, several manufacturers suggest that a value of
1.33 is only a starting point and that a mature process should have an even higher value.
Process Capability Indices
The first indices, Cp and Cpk. As described in the Introduction, the first reference
to capability analysis was in the third edition of Juran’s Quality Handbook published in
1974 (Kotz et al., 2002). In the fourth edition, Gryna (1988) discussed the capability
index that defines this index as the tolerance spread divided by 6σ as described earlier.
More importantly, Juran and Gryna introduced into their handbook the capability
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concepts developed by Kane (1986). Kane’s article is seminal because it laid the
foundation for all further developments and extensions of PCIs.
Kane (1986) pointed out that one of the major problems with Cp is that while it
measures capability, it gives no indication at all of if a process is in control. Sullivan
(1984) had reached the same conclusion. A Cp of 1.33 would indicate that the tolerance
spread is 1.33(6σ) = 8σ wide. For simplicity, set the desired output at 25 units of some
measure, hundredths of an inch, millimeters, ounces, etc. Assuming a σ of one, an LSL of
21 and a USL of 29 would result in a Cp of 1.33 because the difference between the limits
is eight. However, a process with a mean of 50 units and a standard deviation of one
would also have the same Cp.
In his development of Cpk, Equation 2, Kane (1986) used the mean, μ, to locate
the output of the process. He also divided the tolerance spread into two intervals, μ - LSL
and USL - μ. The two intervals reduced the denominator of the expression by a half. It
now equaled 3σ instead of the 6σ of the natural tolerance. This division then defined two
new indices, CPL = (μ - LSL)/3σ, and CPU = (USL - μ)/3σ. Cpk is the minimum of these
two indices. For Cpk to take on a positive value, the value of σ must be between the
specification limits.
Determine the midpoint of the specification range by adding the LSL and the USL
and dividing by two (Kane, 1986, pp. 45-46),
M =

(USL + LSL)
.
2

(7)
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Kane used an m to indicate the value in Equation 3. Authors writing since then have
followed the convention of using M for this value. This use of M is a convention followed
throughout this dissertation.
Using these results, Kane defined a factor, k, used to relate Cp to Cpk (p. 46),
k=

M −µ
,
USL − LSL
2

(8)

C pk = C p (1 − k ) .

(9)

Kane stated this without proof. Bothe (2001) does provide a proof of the relationship.
Kane’s (1986) other contribution is the identification and use of a target value, T,
in evaluating a process. This T value is the desired value of the outcome of the process. If
the specification calls for a value of 0.250 inches, T = 0.250 inches. This use is in contrast
to the previous use of μ, the mean of the process output regardless of how close it is to the
desired value. An implicit assumption Kane made in his derivation is the centering of T
between the LSL and the USL, although he does allow for cases where this is not true.
Other authors, discussed later, examined in more detail situations where this assumption
did not hold. Using the target value, T, Kane offered an alternative formulation of k (p.
46),
k=

µ −T

Min{T − LSL, USL − T }

(10)

Through substitution in Equation 5, Kane (p. 48) showed,

C pk = Min{CPL, CPU} ,
where,

(11)
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CPL =

T −µ 
T − LSL 
1 −

3σ  T − LSL 

(12)

CPU =

USL − T
3σ


T −µ 
1 −

 USL − T 

(13)

Kane (1986) offered several cautions in the use of the indices he documented.
First, there may be pressure to apply the indices too soon before the process is under
control. His equations are based on a mature, in-control process as indicated by the use of
μ and σ rather than X and s. Second, he acknowledged that sampling often yields the
values of these parameters and that the size of the samples could affect their values and,
consequently, the values of the indices. Third, he was concerned about the difficulty of
calculating indices; the later availability of cheap computing power remedied this
concern. Fourth, he expressed reservations about the normality of the processes, and the
effects nonnormality would have on the accuracy of the indices. Fifth, he recognized that
manufacturing methods could change, even over the short term. The specific example he
used addressed how tool wear might affect a process and cause changes to the values of
the indices over time.
Kane (1986) clearly recognized that PCIs had some serious shortcomings. Other
researchers identified this as well. Gunter (1989a, 1989b, 1989c, 1989d) wrote a four-part
series criticizing Cpk in Quality Progress. His concerns about the use of the index
reflected some of those expressed by Kane (1986).
Kane recognized that the index was only suitable for processes that fit a normal
distribution. Gunter reinforced this concept and elaborated by noting that relying on the
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central limit theorem, a frequently applied tool in SQC, does not present an acceptable
solution. Instead, he suggested that data transformations, if they apply to the data under
analysis, might offer a solution, as might robust methods. Kane expressed concern about
the effect of different sample sizes on the calculated values of the indices. Gunter also
cited sampling as a possible source of inaccuracy, but his reservation focuses on sampling
error rather than on sample size. Gunter, also, like Kane, recognized the use of this index
in calculating capabilities for processes that were not yet under control to be a major
source of error.
Interestingly, by the time of Gunter’s article, others were beginning to suggest
alternatives to Cpk to overcome these difficulties. For his criticism of the use of the
central limit theorem, Gunter referred his readers to another article in which Chan,
Cheng, and Spiring (1988a) mathematically showed the inapplicability of this theory to
the calculation of Cpk. However, Gunter did not discuss the alternative the latter article
suggested, Cpm.
The incorporation of a target value, Cpm. Kane (1986) did introduce a PCI
expression incorporating a target value, T. Taguchi (as cited in Boyles, 1991) was the
first to use the measured deviation from T as a penalty factor in the calculation of an
index. According to Boyles, Taguchi focused on the cost of poor quality, either as a
financial impact on the firm or to society in general. Thus, Taguchi’s formulation
incorporated a cost factor. Adding the cost factor differed from the other authors
reviewed here who used PCIs as methods to monitor the performance of a process
without examining any cost considerations. Taguchi introduced his work at the American
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Statistical Association Annual Meeting in 1985. The first journal article incorporating T
reported the research of Chan et al. (1988a). Their research was independent of Taguchi’s
earlier research (Boyles, 1991).
Chan et al. (1988a) developed a new process indicator that reflected the effect of
the process mean missing the target value. It also incorporated the natural variation
around the process mean. The focus was on expanding the ability of Cp to include a
penalty of the value of the indicator based on the distance of the process mean from the
target. They did this by defining a new index, Cpm, defined as (p. 164),
USL − LSL
,
Cˆ pm =
6σ '

(14)

where the definition of σ ′ is (p.164),

σ ' = E( X − T ) 2 .

(15)

σ ′ is estimated with Equation 16,
σˆ ′ =

n (x − T )2
i

∑

i =1

n −1

(16)
.

Referring to Equation (1), we would estimate Cp as (Kane, 1986, p. 42),
USL − LSL
Cˆ p =
6s
,

(17)

where s is the sample standard deviation,

s=

n (x − x)2
i

∑

i =1

n −1

(18)
.
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Comparing Equations 14 and 16, it is apparent that the difference between the two
is that the denominator of Ĉ p increases with the sample standard deviation resulting in a
lower value. Conversely, a smaller standard deviation will result in a higher value of Ĉ p .
The value of Ĉ p depends only on the specification limits, set by engineering, and the
value of the standard deviation, a process characteristic. It is thus independent of the
desired output value from the process, that is, T.
Ĉ pm , on the other hand, is calculated by using the average distance from T. The

closer the distribution of the output is to T, the smaller the denominator becomes, and the
larger Ĉ pm becomes. The greater the spread of the output is with respect to T becomes,
the smaller the resultant value of Ĉ pm . If the mean of the process is equal to T, or at least
very close when compared to the tolerance interval, the Cpm is equal to Cp. Chan et al.
(1988a) showed that (p. 164),

C pm =

[USL − LSL]
6 σ + (µ − T )
2

2

Cp

=
1+

(µ − T )

2

.
(19)

σ2

They also showed that the bias of Ĉ pm as an estimator of Cpm asymptotically
approaches zero as the sample size increases and does so more rapidly than Ĉ p does for
Cp. They also pointed out that while Cp does not change as the mean of the process
changes, Cpm does and does so in a manner similar to Cpk. Boyles (1991) indicated that
this is true only by meeting their assumption that μ = T.
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Boyles (1991) explored several aspects of PCIs involving a targeted process
value, T. Consider Cp and the case where M = μ with a normal distribution assumed. In
this instance, a Cp of one would place the center of the distribution midway between the
specification limits. Calculate a Z-score for a specification limit by taking the distance
between μ and the specification limit and dividing the result by the σ. Φ (Z) represents the
cumulative distribution for this value. Applying this to the calculation of Cpk, Boyles
expressed the percentage conforming as (p.18),
  USL − µ 
 LSL − µ 
%Yield = 100 Φ 
−Φ
 .

 σ

  σ

(20)

He also showed that this establishes upper and lower bounds on the yield of a process
with Cpk values calculated for both the upper and lower specification limits. He
concluded that Cp provides an estimate of the yield the process could achieve, while Cpk
indicates the actual yield limits of the process for particular values of this PCI.
Boyles (1991) noted interesting behavior for both Cpk and Cpm using a plot of the
value of these indices as of function of μ and σ. For any constant σ, Cpk will reach its
maximum when μ = M, Equation Error! Reference source not found.. At this point, Cpk
= Cp while at or beyond both specification limits, Cpk = 0. At any constant value of μ,

lim C pk = ∞

σ →0

(21)

Because Cpk can increase without bound in this situation, Boyles suggested that it does
not serve well as an indicator of the centering of the process or the distance between the
mean of the process and T.
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Boyles (1991) considered Cpm to be a better indicator of process centering. He
analyzed Cpm similarly to the analysis of Cpk. Consider Cpm as a function of μ and σ. For a
constant value of σ, Cpm will reach its maximum value when μ = T = M. Cpk equals zero at
or beyond the specification limits. Cpm will approach zero as the distance between μ and T
increases,

lim

µ −T → ∞

C pm = 0 .

(22)

Boyles (1991) indicated that there is an upper bound to Cpm as σ approaches zero
(p. 20),

C pm <

USL − LSL
.
6 µ −T

(23)

However, this is only true in cases where μ is not equal to T. Cp would be a line parallel
to the μ – Cpk or μ – Cpm planes. This line intersects the vertex of the angle of the plot of
Cpk or tangent to the circles formed by the plot of Cpm. Cutting planes construction
parallel to the μ – σ plane, results in those found in Boyles (1991).
Refining the target value, Cpmk. Pearn et al. (1992) found inconsistencies in both
the prior work of both Kane (1986) and Chan et al. (1988a). These discrepancies
concerned the percentage of non-conformance versus the value of the PCI. They
considered cases where T lies within the specification limits but is not equal to M. Half
the distance between the specification limits is (p.217),
d =

USL − LSL
2

(24)
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If d = 6σ, and T = 3[(USL) + LSL)]/4 (p. 218), then if μ = T - d/2 = M (p. 218) and
μ = T - d/2 = USL (p. 218), it can be shown that the values of Cpm are equal to 2 / 13 =
0.555 for both values of μ. This is due to the (μ - T)2 term in the denominator of the
expression for Cpm. While the values of Cpm are equal, the percentages non-conforming
are 0.27% and 0.50% respectively as shown in Figure 3.

Figure 3. Process with identical Cpm values, but differing percentages conforming.
To overcome these problems, while restricting their proposal to the case where T
= M, Equation 7, they developed a new index, Cpmk. Defining σ ′ as, σ ′ = σ 2 + ( µ − T )2
(p. 217),
C pmk =

min(USL − µ , µ − LSL )
=
3σ ′

with an estimator of (p. 221),

C pk
 µ −T 
1+ 

 σ 

,
2

(25)
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Cˆ pmk =

d − X −M
1  n

2
3
∑ (X i − X ) + n(X − T ) 
n i =1


,
(26)

where (p. 217),
d =

USL − LSL
2

(27)

As is the case with Cpm, deviations from T induce a penalty in the form of a larger
value of the index. The authors indicated that Cpmk is the most sensitive of the four
indices to values that deviate from the target value, T, followed by Cpm, Cpk, and Cp. They
further identified Cp as the first-generation index, Cpk and Cpm as the second generation,
and Cpmk as belonging to a third generation.
A unifying index, Cp(u, v). Writing after Boyles (1991), and Pearn et al. (1992),
Vännman (1995) developed a unified approach to PCIs. To avoid the problems
highlighted by Pearn et al. (1992), he assumed that T = M and normality (p. 807),

C p (u , v ) =

d −uµ −M
(28)

3 σ 2 + v( µ − T ) 2

This equation can generate all of the capability indices considered so far,

C p (0,0) = C p ;

C p (1,0) = C pk ;

C p (0,1) = C pm;

Cp (1,1) = Cpmk,

(29)

by using different values of u and v.
An advantage of Vännman’s (1995) approach is that the possible adjustment of
the values of u and v to increase or decrease the sensitivity of the index. This adjustment
is to the distance between M and T. Vännman pointed out that this is especially important
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when dealing with a small value of σ. Use of Vännman’s expression of capability indices
in terms of u and v has become very common in the literature.
A fourth generation index, Cpsk. A year before Vännman’s (1995) article
appeared, Benson (1994) completed a doctoral dissertation that proposed a fourth
generation index. What makes this dissertation noteworthy is that Samuel Kotz, who,
along with Pearn and Johnson, made major contributions to the development and
exploration of indices, was Benson’s co-chair. In fact, in the index Benson proposed,
Cpsk, sk stands for Samuel Kotz.
Benson’s (1994) index was similar to that of Vännman’s with the addition of
another parameter, w, (p. 44),

C p (u, v, w) =

d − wµ −T − u µ − M
3 σ 2 + v( µ − T ) 2

.

(30)

Benson did refer to previous work by Vännman discussing the index. Benson showed that
the inclusion of the w parameter allows for the case M ≠ T. Under assumed normality, the
addition of the w parameter extracted an additional penalty. This penalty applied to the
differences between the mean and the target, T.
Unlike other indices, Benson’s did not assume that the target lies at the midpoint
of the specification range. Like Vännman’s (1995) index, Cp (u, v), appropriate values of
u, v, and w will yield the other indices.
Basic indices conclusions. This section has examined the basic capability indices.
While their evolution has made them more sensitive to process irregularities, one thing
remained constant: An assumption of normality is the basis for these indices. With a
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failure of that assumption, the results of a capability analysis may be misleading at best
and dangerous at worst. In the medical field, relying on incorrect results can endanger
patient lives and expose a manufacturer to serious legal and financial liability.
After the development of the basic indices, Kotz and Lovelace (1998) found “The
avalanche” (p. 95) of indices began. The reference is to indices developed to cope with
the shortcomings of the basic versions. New indices continue to be developed (Lupo,
2015). The next section will address methods to compensate for the lack of normality in
the use or development of PCIs including addressing nonnormal data in general.
Overcoming Nonnormality
Fortunately, problems with nonnormal data are not restricted to the examination
of the output from manufacturing processes. Instead, they are attracting considerable
attention from statisticians and researchers in other fields who have developed methods
for addressing this problem. The methods developed in other fields can also apply to PCI
calculations. While the study of process capability is relatively recent, the study of
nonnormality is not. Pearson (1894, 1901, 1916) opened this subject to review. Prior to
Pearson’s research, scholars held that all probability distributions were normal but with
differing amounts of skew (Department of Statistics, University of Minnesota, Morris,
n.d.). Pearson developed descriptions for several different types of frequency
distributions, including the normal distribution, according to their skew and kurtosis.
Statistician, including those studying PCIs, widely use Pearson’s method and its variants.
Transformations, including percentile methods. One of the most widely used
methods for addressing nonnormality is that of transforming the data. If the application of
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a transform achieves normality, then a practitioner can apply a capability index to the
transformed data and specification limits to assess the capability. Two methods, the
Johnson, and the Box-Cox transformations, are very widely used. Many statistical
packages, for example, Minitab (2010), incorporate both of these methods.
The first method discussed, developed by Johnson (1949), is similar to the
approach taken by Pearson (1894, 1901, 1916) in that he also used the moments to
develop his frequency curves. He provided a method to translate curves so that they will
coincide with Pearson curves, ideally that representing the normal distribution. Although
the transformation is simple in appearance, (Johnson, 1949, p. 152), it is rather complex,

 x −ξ 
z =γ + f
.
 λ 

(31)

Like Pearson, the skew and kurtosis are calculated. Johnson (1949) then provided
a lookup table for these values, depending on the type of curve under analysis, allowing
the determination of the other parameters, and the data transformation. In total, he
developed three transformations SB, SL, and SU. Slifker and Shapiro (1980) provided a
more detailed explanation of the procedure and its application. A frequently cited article
using this method is Pyzdek’s (1992).
The other common transformation is the Box-Cox (Box & Cox, 1964, p. 214).

y

(λ )

 ( y + λ2 ) − 1

=
λ1
 log y

(λ ≠ 0)
(λ = 0)

(32)
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With different values of λ, the transform takes on different characteristics. For example, a
value of 0.50 will result in a square root transform, and a value of -0.50 is the reciprocal
square root transform. Wu, Lin, Yang, and Pearn (2014) reported a recent application of
the Box-Cox transformation to Cpk calculations.
The need to address general problems of nonnormality in statistical analysis led to
the development of these methods. Along with these, other types of simple transforms
exist. For example, a trigonometric function can be applied to the data and the
specification limits. It is important to note that making any adjustments, for example to
the specification limits, require back transformation before use. Kabacoff (2015)
expressed caution about justifying transformations before applying them. Other methods,
discussed later, address the problem of nonnormality as it applies to quantifying process
capability.
Applications based on Pearson probability distributions. Clements (1989)
developed a method based on Pearson’s (1894, 1901, 1916) system using the calculations
for this method done by Gruska, Mirkhani, and Lamberson (1979). Clements’s method
first required the calculation of the mean, X , the sample standard deviation, s, the
skewness, Sk, and the kurtosis, Ku, for the data. He used these values to create
standardized values. Users apply the values by looking them up in the appropriate tables
published in his article, adapted from the tables found in Gruska et al (1979).
The values from the tables correspond to the 0.00135 and .99865 percentiles that
are the values for 3σ in either direction from the mean of a normal distribution. Clements
designated these as L′p and U′p respectively. Taken individually, they corresponded to the
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values needed to calculate CPU and CPL; when combined, they gave the 6σ value
required to calculate Cp.
Next, one looked up the value of the median in another provided table.

M ′ designates this value after adjusting the sign for either positive or negative values of
skewness. The values of Lp, Up and M are calculated from these values (Clements, 1989,
p. 97).
L p = X − sL p ′ ,

(33)

U p = X + sU p ′ ,

(34)

M = X + sM ′ .

(35)

These represented the values of the percentiles and the estimated median of the
distribution. Given upper and lower tolerance (UTL or LTL) or specification limits (USL
or LSL), represented as Ut and Lt respectively, the PCIs were calculated as (p.97),
Cp =

CPL =

(U t

− Lt )
,
U p − Lp

(

)

(M − Lt ) ,

(M − L p )

CPU =

(U t

(37)

−M)
,
Up −M

(

(36)

)

C pk = Min(CPL, CPU) .

(38)
(39)

These equations correspond to Equations 1, 3, 4, and 5.
Publication of Clements’ (1989) article followed that of Chan et al. (1988a) by a
year. It, understandably, did not include any of the calculations found in that article for
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Cpm equivalents. Because it preceded Kotz et al. (1993), it did not contain any references
to Cpmk. It is an important article that laid the foundation for other research that expanded
Clements’ methodology.
Pearn and Kotz (1994) filled this Cpm gap by modifying the indices Cpm and Cpmk
to incorporate Clements’ method. They used the percentile points generated through the
application of Clements’ method and the median, M, in place of the mean, µ. The results
were (Pearn & Kotz, 1994, p. 142),
Cˆ pm =

(USL − LSL )
 U − L 

(
2
p
p)

6 
 + (M −T ) 


6



2

Cˆ *pm =

min [USL − T , T − LSL ]
 U − L 

(
2
p
p)

3 
 + (M −T ) 


6



2

Cˆ pmk

1
2

1
2

,
(40)

,









USL − M
M − LSL

,
= min 
1
1
 
2
2
 2  M − L 
2 
(
   (U p − M ) 

2
2
p)
 + ( M − T )  3 
 + (M −T )  
 3 



3
3


  


 

(41)

(42)

.
Pearn and Chen (1995) refined the method. Instead of treating using Up – M and M – Lp
as the value of 3σ, they replaced the two 3σ intervals with (Up – Lp)/2. The resulting
equations, now including expressions for Ĉ p and Ĉ pk , were (p. 387),
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USL − LSL
Cˆ p =
U p − Lp

(43)

min(USL − M , M − LSL)
Cˆ pk =
(U p − L p )

(44)

2
Cˆ pmk =

min(USL − M , M − LSL)
 U − M 

(
)
2
p

3 
 + (M −T ) 


6



2

1
2

.
(45)

Expressed in Vännman’s (1995) notation, these are (p. 387),
Cˆ p (u , v ) =

[

d −uM −m

6 (U p − L p ) / 6

]

2

+ v( M − T )

.
2

(46)

In this same work, Pearn and Chen (1995) proposed a method for asymmetric
tolerance intervals. Independently, Vännman (1997) also addressed this topic by building
on his original (1995) work by using different values of u and v. Pearn, Chen, and Lin
(1999) refined the research they had done in the asymmetric case by incorporating some
of the ideas of Vännman (1997). This incorporation of Vännman’s work resulted in a set
of indices that outperformed all earlier efforts for the asymmetric case.
Applications based on Burr cumulative distributions. Most of the applications
of percentile methods have used Pearson probability distribution curves. The evaluation
of process capability can also use the distribution curves of Burr (Burr, 1942, 1973; Burr
& Cislak, 1968; Zimmer & Burr, 1963).
Burr and Cislak (1968) proposed the equation (p. 629) to explain its use,
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F ( x ) = 1 − (1 + x c ) − k
=0

x≥0
x<0

c, k > 0

.

(47)

Given a data set, the mean, μ, the standard deviation, σ, the user calculated the skewness
(referred to by Burr, 1942, as α3) and the kurtosis (referred to by Burr as α4). Using the
values of α3 and α4, find the values of c and k. Burr’s Table 1 gave the adjusted μ and σ.
With these values, the final calculation uses Equation 48 (Burr and Cislak, p. 629),

( X − X ) (x − µ)
=
,
sX
σ

(48)

to find x from X.
The first application of Burr’s method to capability indices appears to be
Castagliola (1996) who used it in evaluating CPL, CPU, Cp, and Cpk for both normal and
uniform distributions. He noted in his conclusions that to assess its performance for other
nonnormal distributions would require further research. A succinct explanation of the
mechanics of Burr’s method to capability indices is in Liu and Chen (2006). They found
that this method offered superior results to those using the Pearson curves for the
calculation of capability indices. Their application processed data simulated by the beta,
gamma, and Weibull distributions.
Weighted variance methods. Control charts and PCIs share common roots. The
most common control chart, the X − R , is based on the mean of the mean of the output of
a process. It also uses the range covered by the samples taken to monitor the process. The
weighted variance approach is somewhat similar to the utilization of the mean and
standard deviation in capability indices that, at their simplest, quantify the number of
standard deviations between the specification limits.
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Using earlier research (Choobineh & Branting, 1986), Choobineh and Ballard
(1987) proposed a method for constructing control charts for skewed, that is, nonnormal,
distributions. Given a sample mean, one counted the number of observations above the
mean and divides by the number of total observations to derive a value P, the probability
of the observation falling above the mean. Then, the probability of an observation falling
below the mean is 1 – P.
The standard deviation of the entire distribution, σx, is broken into two
components, σa and σb, located above and below the mean respectively. Choobineh and
Ballard (1987) further indicated that (p.475),
σ x2 = σ a2 + σ b2 ,

(49)

σ a2 ≈ P σ x2 ,

(50)

σ b2 ≈ (1 − P )σ x2 .

(51)

The upper control limit factor is 2 P , and the lower control limit factor 2(1 − P) .
These, taken with a correction factor (p. 475), A = 3 / n , generated the upper and lower
control limits for the mean and the range.
Abel (1989) was critical of Choobineh and Ballard (1987). Among other
objections, he indicated that the calculations of the standard deviations were incorrect and
the use of the factor A, was not accurate. Shewhart control charts use the factors A2, D3,
and D4 (Montgomery, 2013). These contain anti-biasing corrections for the distribution of
the standard deviations. Choobineh and Ballard’s (1987) factors do not. For information
regarding the mathematics behind Abel’s objection, see NIST/SEMATECH (2015).
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Bai and Choi (1995) and Chang and Bai (2001) refined the weighted variance
method of Choobineh and Ballard (1987) for control charts. Later, Chang, Choi, and Bai
(2002) applied weighted variance to the construction of PCIs involving skewed
distributions. Chang and Bai (2001) split a skewed distribution, f(x), at the mean, μ, and
derived two probability density functions using the same mean as f(x). They reflected the
distribution around the mean, incorporating the probability, P, of the value being to the
left of the mean. These distributions will have different standard deviations because they
have differing shapes (p. 398),
 1
 2(1 − P ) f ( 2 µ − y ), y ≤ µ
,
gU ( y ) = 
1

f ( y ), y > µ
 2(1 − P )

(52)

 1
f ( y), y ≤ µ

g L ( y ) =  2P
,
1

f (2µ − y), y > µ
 2P

(53)

Chang and Bai (2001) derived the standard deviations from these equations. They
used the semivariance expression from Choobineh and Branting (1986). They calculated
weighted standard deviations for the upper and lower standard deviations (p. 399),

σUW = Pσ ,

(54)

σ LW = (1 − P )σ .

(55)

Using these two σ values in the equation for the normal distribution, with mean μ,
the results gave the two probability distribution functions arising from the rotations. Use
the values in Equations 54 and 55 to determine the control limits for the control chart.
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Chang et al. (2002) extended this work to PCIs. Building on the work of Chang
and Bai (2001), they derived expressions for a Cp and Cpk equivalent indices (p.365),
 USL − LSL USL − LSL  USL − LSL
 1

1
C WSD
= min 
,
min 
,
=
.
p
W
W
6(2σ L ) 
6σ x
 6(2σ U )
 2 Px 2(1 − Px ) 

(56)

If Dx = 1 + 1 − 2Px , then,
C WSD
=
p

Cp

(57)

Dx

USL − µ x µ x − LSL 
WSD
C WSD
,
= min {C WSD
.
pk
pku , C pkl } = min 
 6 Pxσ x 6(1 − Px )σ x 

(58)

This weighted value is unlike the simple Cp, and variants, considered previously. Those
WSD
calculations give only one value for the index. C p gives a value for each of the

distributions generated by rotation around the mean and selects the smaller one.
Building on earlier research, Wu (1998), and Wu, Swain, Farrington, and
Messimer (1999) took a different approach to the development of an index based on
weighted variance. The approach was unlike that later taken by Chang et al. (2002).
Similar to the other methods, they identified the number of observations below the mean
as n1, and above the mean as n2. The sample standard deviations below and above the
mean are (p. 399),
n1

2 ∑ (X i − X )

S12 = i =1
2 n1 − 1

2

,

(59)
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n2

2 ∑ (X i − X )

2

S 22 = i =1
2n 2 − 1

(60)

.

For indices involving a target value, T, they used (p. 399),
n1

2 ∑ ( X i − T )2

S T21 = i =1
2 n1 − 1

=

2 n1 − 1 2
2
S1 + ( X − T ) ,
2 n1

(61)

=

2n 2 − 1 2
2
S 2 + (X − T ) .
2n 2

(62)

n2

2 ∑ ( X i − T )2

ST2 2 = i =1
2n2 − 1

For all of these equations, the Xis would be those corresponding to those counted by n1
and n2 respectively.
Using these S values for the standard deviations, the PCIs became (p. 399),

USL − LSL
Cˆ p (WV ) =
,
3( S1 + S 2 )

(63)

USL − X X − LSL 
Cˆ pk (WV ) = min 
,
,
3S1 
 3S 2

(64)

USL − T T − LSL 
Cˆ pm (WV ) = min 
,
,
3ST 1 
 3ST 2

(65)

USL − X X − LSL 
Cˆ pmk (WV ) = min 
,
.
3
S
3ST 1 

T2

(66)

The Bootstrap Method
Another method for the evaluation of nonnormal data, not explored in depth in
this dissertation, is the bootstrap. Efron and Tibshirani (1993) provided a thorough
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description of the technique. Franklin and Gary (1991) applied the method to simulated
data from the normal, the t, and the chi-squared distributions. They calculated 96%
confidence intervals for Cp, Cpk, and Cpm from the data. Price and Price (1993) used the
method to examine quality data from a Ford Motor Company engine casting plant. In this
study, they used the method to construct 95% confidence intervals for Ĉ pk .
Pearn et al. (2005) implemented the method to examine asymmetric tolerance
intervals for nonnormal data. Their efforts produced a new PCI for this application,
′′ ( u ,v ) . Pearn, Tai, Hsiao, and Ao (2014) applied the method to simulated data to
C Np

develop a confidence interval, and a new, unbiased estimator for CNpk for nonnormal data.
Tong, Chen, and Tai (2008) used the technique to compare confidence intervals
from different bootstrap samples from the same distributions. Dharmasena,
Zeephongsekul, and Castagliola (2010) implemented the method to calculate fixed-width
confidence intervals for Cpm. They used simulated data from normal and lognormal
distributions.
Robust Methods
Like the weighted variance techniques, the development of a median absolute
deviation (MAD) approach to process capability began with the application of the method
to control charts. Abu-Shawiesh (2008) proposed the substitution of the average MAD,
with an appropriate adjustment factor he provides, for the adjusted standard deviation in
the construction of an s-like control chart. The calculation of the sample standard
deviation used the provided factors and the standard c4 bias correction factors. The schart represents a plot of the movement of the standard deviation of samples taken from
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the process compared to the average standard deviation. In a simulation study, AbuShawiesh showed that the MAD based control chart performed better for heavy-tailed
distributions than did the s-chart. This advantage applied to contaminated distributions
because they may have heavier tails than a pure normal distribution does.
Adekeye and Azbuike (2012) extended the work of Abu-Shawiesh (2008) to
allow the creation of X control charts. X refers to the average of the averages of X.
Adekeye and Azbuike modified the correction factors developed by Abu-Shawiesh. The
new charts use the X as the centerline with the control limits derived from the MAD
using the new correction factors. Adekeye (2012) further refined the correction factors to
improve the performance of these control charts.
Adekeye (2013) extended the concepts behind the MAD control charts to include
PCIs and developed variants of Cp, Cpk, Cpm, and Cpmk. In the new indices, he applied
appropriate correction factors from Abu-Shawiesh (2008) to the mean MAD and the
resultant expression substituted for the value of σ in the equation. Adekeye used the
technique on four data sets, two real-world, one using data simulated with an exponential
distribution, and another using data simulated with a Weibull distribution. He compared
these with comparable indices calculated using a percentile method.
For the first real-world set, the MAD Cp and Cpm were lower than the equivalent
indices, Cpk was equal, and Cpmk was higher by roughly a third. For the second real-world
data set, the MAD indices were all lower by 40 to 24 percent. For the simulated data, the
MAD indices were higher than the percentile indices, in one case by 150 percent. While
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Adekeye considered the PCI higher values in the latter two cases to be an advantage, his
work showed that the use of these indices requires caution.
Mondal, Ray, and Maiti (2014) offered general guidelines for the incorporation of
robustness in manufacturing that goes beyond the step of calculating a PCI. Besseris
(2014) proposed a modification of existing indices to further improve the robustness of
the calculations. Salazar-Alvares and Temblador (2012) provided a general review of
PCIs and nonnormal processes.
The Performance of the Different Indices and Methodologies
Throughout their development, researchers have subjected PCIs to testing and
scrutiny. These activities led to the development of new indices and methodologies.
Much of this activity has centered on the performance of the indices when the data is
nonnormal, including data from industry.
English and Taylor (1993) explored the performance of Cp and Cpk for nonnormal
simulated data from the triangular, uniform and truncated exponential distributions. As a
control, they also generated simulated data using the normal distribution. They ran 20
different models with sample sizes varying from small to large. They concluded that the
indices were sensitive to the normality assumption. Cpk is the more sensitive of the two.
They cautioned those who might use these indices to be very careful when working with
nonnormal data.
Rivera et al. (1995) examined the performance of Cpk for transformed data
generated by simulation from the gamma, lognormal, and Weibull distributions. They
used logarithmic, square root, inverse, inverse square root, asinh, and power
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transformations. The authors emphasized that they examined all transformed data for
normality before any testing. Keselman, Othman, and Wilcox (2013) reinforced the
importance of this procedure. Rivera et al. (1995) reached the conclusion that a power
transform performed best, although problems arose with insufficient shortening of the tail
resulting in overly conservative Cpk values. This observation lends validity to the
sampling effect concern first voiced by Gunter (1998b).
Tang and Than (1999) studied several different methods of overcoming
nonnormality. They applied probability plots, weighted variance, Clements’s method, and
the Box-Cox and Johnson transformations. They used these methods on data simulated
from lognormal and Weibull distributions. They concluded that the Box-Cox
transformation, a power transformation, performed best. This performance differential
was especially apparent for the heavy-tailed lognormal data.
Pal (2005) used the Generalized Lambda Distribution (GLD) method to examine
nonnormal data of the length of bolts produced by a process under study. The GLD
method is similar to the curve fitting of the Johnson transformation and the percentile
calculation of Pearson curves. He concluded that this method was computationally
simpler than the other two approaches. He calculated Ĉ pk using his method and it
showed that the process did not meet the requirement of Cpk ≥ 1.33. Unfortunately, he did
not compute Cpk using the traditional approach for comparison.
As previously mentioned, Liu and Chen (2006) applied a method using the Burr
XII distribution to data simulated using the beta, gamma, and Weibull distributions. They
compared the results to those reached using Clements’s method. They concluded that,
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though both methods overestimate CPU, especially for heavily skewed distributions, the
distortion was less using his modification of the Burr method. They deduced that the Burr
method would offer more satisfactory results than Clements’ for practitioners.
Han (2006) used simulated data and evaluated it using the Shapiro-Wilk test for
normality. His conclusion was that if the data passes the test for normality use the
standard PCI based on the estimated standard deviation. If the test indicates
nonnormality, he recommended the use of a percentile-based method. The focus of his
article is more on the importance of the accuracy of the test for normality, and the
selection of the correct significance level, than the performance of the capability indices.
Czarski (2008) compared the results of calculating Cpk using percentiles
calculated from a nonnormal distribution with the results reached through the application
of Clements’s method. The object of his research was the thickness of rolled steel plate to
which he had empirically fit a Weibull distribution. He found that there was very little
difference between the results of the two methods.
Czarski (2008) concluded that, in the case of nonnormal data, it is a mistake to
apply methods based on the normality assumption. Instead, fit a distribution if possible,
and carry out the calculations based on that distribution. Alternatively, the use of
Clements’ method may offer close enough results for use as a viable alternative.
Hosseinifard, Abbasi, Ahmad, and Abdollahian (2009) performed a study with
two components that compared the results of different methods of dealing with
nonnormality first on simulated data, and then in a real-world application. They simulated
the data using the gamma, Weibull, and beta distributions. They evaluated four methods
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of coping with nonnormality, the root transform, the Box-Cox method, and two percentile
methods based on Burr and Clements. Their root transform was different from that
previously discussed in Rivera et al. (1995). In Hosseinifard et al.’s (2009) use, a fraction
power transformation minimizes the value of the skewness. The concept behind this is
that an adjusted normal distribution has a skewness of zero.
Hosseinifard et al. (2009) achieved the best results for the simulated data using
the root transformation. They then applied the different to the real-world data, which
dealt with contact area in the semiconductor manufacturing industry, and achieved
similar results. Their recommendation was that practitioners consider using the root
method when dealing with nonnormal data, claiming that it not only gave better results,
but also was easier to use.
Kenyon and Sale (2010) developed an index, Cpy, based entirely on the yield of a
process. Their claim was that the index’s base is the hard yield. Hard yield is the amount
of product produced between the specification limits, compared to the total produced.
This comparison made the underlying shape of the distribution describing the process
irrelevant. While they stated that a weakness of traditional capability indices is their
reliance that the process is under control, others could make the same objection toward
their approach. Maiti, Saha, and Nanda (2010) took a similar approach, with the
denominator representing the expected process yield.
Goswami and Dutta (2013) compared the results for the calculation of Cp and Cpk
for data from a chemical manufacturing process fitted to gamma and Weibull
distributions. Methods used were the Box-Cox and Johnson transformations, an “ISO”

67
method apparently based on the percentiles from the two fitted distributions, and
Clements method. The “ISO” method yielded the lowest indices that may have been due
to the poor fit of the distributions. The other methods produced index results that were
similar to each other and considerably higher than those generated by the “ISO” method
were.
Kovářík and Sarga (2014) used simulated data from Weibull and lognormal
distributions to evaluate the performance of nine different methods, broken into what the
authors described as nontransformation and transformation, to overcome nonnormality.
The nontransform approaches are a probability graphing method developed by the
authors, a tolerance interval/graphical approach from Chan et al. (1988b), weighted
variance, and Wright’s index (1995). The methods classified as transforms include
Clements and Burr-based percentile methods, and several other transformation techniques
including Box-Cox and Johnson. The authors studied the index Ĉ pu .
Kovářík and Sarga (2014) concluded that, while non-transformational methods
may offer computational simplicity, they do not perform as well as transform methods
unless the data are close to normal. Transformation methods, particularly Box-Cox,
generally did better than non-transformational methods. The authors found that their
accuracy was sensitive to sample size, with better results coming from larger samples. If
there was a requirement for small sample sizes, methods using Burr distributions yielded
more accurate index estimates.
Safdar and Ahmed (2014) examined the effects of the shape parameter of the
Weibull distribution on Cp, Cpk, Cpm, and Cpmk. As expected, they found that it did have an
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impact on the estimation of the indices but found that sample size had little or no effect
on the values. This lack of influence was in contrast to the findings of several other
authors, for example, Kovářík and Sarga (2014) who found such an effect.
Contaminated distributions. Contaminated distributions are combinations of
distributions. Tukey (1960, p. 454), showed the form of the probability density function
for a mixed normal distribution as,

nγ , h ( z )dz = (1 − γ )

1
2π
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−
e 2

dz + γ
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h 2π
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e

z2
2h 2

dz .
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In this equation, γ is the fraction of the total from the wider distribution that has a scale h
times broader than the other. A thorough review of the literature has shown that little
research relating this condition to PCIs. Bothe (1999) did consider the selection of
samples from multiple process streams and developed a method based on a weighted
average of nonconforming parts across the streams. His work did assume a known
number of elements from the different streams. Although the contaminated distribution
represented above indicates known probabilities for each distribution, in a mixture of lots
from an upstream supplier this might not be the case.
Summary and Conclusions
This chapter included a discussion of the development of several approaches to
the measurement of process capability. PCIs began as a simple indicator developed by
Kane (1986). Since then, PCIs have grown to encompass a broad range of process
conditions., and are still considered to be an important part of quality and continuous
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improvement activities (Jaca, Viles, Mateo, & Santo, 2012; Kenett & Zacks, 2012;
Mariappan, Gaonkar, Sakhardande, & Dhawalikar, 2012).
Many of the uses are in very specialized applications. There was no discussion of
many of these specialized indices due to space and, more importantly, scope
considerations. Because PCIs rely on the normality of data, this chapter contained
discussions of several methods for coping with nonnormality, including transformations
and robust methods, as well as weighted variance and bootstraps techniques.
The literature study revealed that many researchers used simulated data to
measure the performance of the various indicators. The use of simulation is a critical
consideration because the actual nature of ill-behaved data in the real-world is seldom, if
ever, known with certainty. Using simulated data provides confidence in the capabilities
of the process and allows the use of that knowledge to evaluate the performance of an
indicator with certainty. Hence, the use of this approach to generate the data used to
assess the PCIs on data from particular contaminated distributions as described in the
next chapter.
A gap in the literature exists in the application of PCIs to medical manufacturing
specifically. The FDA lot traceability requirement offers a leverage point to make the
application of the indices more accurate. This requirement forms the basis for the
methods employed in this study. The next chapter contains a description of these
methods.
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Chapter 3: Research Method
The purpose of this empirical quantitative study was to develop a framework that
evaluated the ability of a PCI to accurately measure medical device test data under a
scenario where output data combines the effects of mixed production lots of components.
The study was comparative in nature. It included an examination of the performance of
the most commonly used PCI, Cpk, using simulated process data by calculating precise
capabilities and then compare these values with the results generated from nonnormal
data adjusted indices. Data consisted of combinations of data from different distributions
representing the situation where a lot of raw material used in a process consists of
material from several supplier lots.
The simulated data represented test values from some production test and are the
independent variables. Using simulated data negates the influence of, or need to control
for, any independent variables, because only the final value of a test is simulated. The
value of the calculated PCI was the dependent variable of interest in this study.
Successful completion of this study offers evidence of the applicability of PCIs to results
that may come from the combination of distributions.
The research involved an examination of the performance of the most commonly
used PCI, Cpk, using simulated process data, as well as a description of the population
data generated through simulation and then analyzed. A subsequent discussion includes
an examination of sample size determination and a description of confidence intervals
and hypothesis tests. The chapter ends with a discussion of the validity of the study and
overcoming the potential threats to the validity.
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Research Design and Rationale
This research was semiexperimental because the data used to answer the research
question were simulated, that is, there was an underlying experiment executed to generate
the samples. The experimental design itself was quasiexperimental because, even though
the simulated data generated to test the hypothesis were random, parameter selection
provided control. This random control qualifies it as a quasiexperimental design.
Device components or finished devices testing requires preset criteria. The
simulated data represented test results and were the independent variable in this study.
These test results might be quantifiable factors, for example, tensile strength, length,
electrical resistance, or weight. The nature of the test process itself is not important. What
is important is that it generates quantitative, rather than qualitative, data measurable on a
scale to ascertain if a datum falls within the specification limits defined by engineering.
The PCIs, variances, and standard deviations calculated from the data are the dependent
variables.
Simulation runs consist of 10,000 data points. This is a commonly used number in
simulation studies; for example, it is the number used by English and Taylor (1993), Han
(2006), and Hosseinifard and Abbasi (2009). The appropriateness of this number would
depend on the medical device manufactured. A discussion in greater detail appears later
in this chapter. However, 10,000 was large enough to determine if the overall approach
taken in this study was valid, but might require some adjustment under specific, large
scale application of the methodology.
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Several factors informed the decision to use simulated data. The first, and most
important, was the ability to control the nature of the data. Because of the examination of
defined distributions during the study, the ability to create test data that would follow
specific distributions when tested would require a great deal of luck. By using simulated
data, with the parameters of the generating distributions known, it was possible to
determine the proportion of the data that should lie above or below a set point, for
example, a specification limit.
Another consideration was the time and expense that would be involved in
generating 10,000 data points for 12 different distributions. Even if the process to make
the parts to be tested was simple, creating 120,000 parts would require considerable time
and expense. After the completion of part manufacturing testing requires additional time.
Methodology
This section contains a description of the methodology used, including the
mathematical model construction, data generated for the study, sampling techniques, and
statistical tests used. I generated the data for this study through computer simulation. The
data represent manufacturing test results applicable to all goods produced through
manufacturing processes worldwide where the raw materials, or components, for the
process, originate in different lots with subsequent mixing in the production process.
While the FDA requires that the lots used in the creation of a subsequent lot be
traceable, a mixture of the lots could occur in production (Identification and Traceability,
2016). See Figure 4 for an illustration.
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Figure 4. Illustration of how components from different lots come together in a
manufacturing process.
This mixing of components can quickly become very complicated. Figure 5
contains an illustration of this lot mixing activity. Each substep uses three lots for
illustration purposes. The number of lots could easily be larger depending on the
complexity of the component manufactured.
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Figure 5. An example of lot mixing in production for a device with four third level
components, two second level components, and o top level finished good.
Sampling and Sampling Procedures
I used R’s (2016) sample function to choose samples from the simulated data.
Four different sample sizes are used: 10, 30, 59, and other values dependent on the
execution of the simulation. A sample size of 10 imitates a convenient number possibly
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selected by an engineer who is statistically naïve. A sample size of 30 represents the
situation where statistics students correctly learn that this is the number at which a t
distribution approximates a normal distribution and use it as a default sample size.
However, this fact does not make it suitable as a sample size in all situations. Cohen
(1990) and Mathews (2010) expressed caution concerning its indiscriminate use as a
sample size. A sample size of 59 is the value that achieves a 95% level of confidence and
a 95% reliability level. Based on the success run theorem (Lipson & Sheth, 1973), the
medical device industry often uses this sample size as a convenience.
The values of the mean and standard deviation generated from these different
sample sizes depend on calculations from samples. The requirement was values that
would represent the expected results generated from samples of these different sizes.
Therefore, sample size calculations are also required to arrive at the values of the mean
and standard deviation for the calculation of the PCIs.
To calculate the sample size for the mean, Mathews’s (2010, p. 8) Equation 1.12
was used under the assumption that the test was being constructed as if it is a two-sided
hypothesis test. The known mean of the underlying standard deviation, 100, is the test
standard, and five is the known standard deviation for this distribution. The difference
between a Cpk of 1.00 and 1.33 is one standard deviation, so the effect size is taken as δ =
5.00. To achieve 95% confidence, and power, π, of 0.90, the sample size calculation is,
 ( zα / 2 + zβ ) σ x
n=

δ


2

2

 (1.96 + 1.282 ) 5.00 
 =
 = 10.51.

5.00




(68)
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This rounded result is 11. Next, a comparison of the calculated sample size for the
standard deviation with that required for the mean determines if it is smaller or larger
than that value. Mathews’s (2010, p. 59) is an appropriate approximate method. For a
95% confidence interval with a confidence interval, δ, of 0.10 of the standard deviation,
the calculation is,
2

2

1 z 
1  1.96 
n =  α /2  = 
 = 192.08
2 δ 
2  0.1 

(69)

A rounded result of 200 agrees with the table of exact results in Mathews (2010).
Because this value of n is greater than that calculated for the mean, it becomes the sample
size for the calculation of the mean and standard deviation of the applied sample sizes.
All further reference to values derived from the different sample sizes refer to the mean
and standard deviation calculated from a sample size of 200. The next section contains an
elaboration on the determination of sample sizes during the simulation.

Sample size determination. The sample size intimately relates to the testing
performed on the PCIs calculated for this study. The comparison of variances is the
principle behind hypothesis testing of PCIs and careful analysis is critical to accurate
results (Álvarez, Moya-Férnandez, Blanco-Encomienda, & Muñoz, 2015). Consider
Equations 1 and 2 (repeated for convenience),
Cp =

USL − LSL
,
6σ

 µ − LSL USL − µ 
C pk = Min 
,
.
3σ 
 3σ
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The value of σ, the square root of the variance, provides the base for both
equations. Mathews (2010) pointed out that these PCIs are arithmetic transformations of
the standard deviations of the output of the process under study. The values of the
numerator of these fractions, combined with a value for the index, define the maximum σ
allowable to meet these conditions. The results for the σ would be directly applicable to
the variance.
The comparison of variances forms the basis for the hypothesis test using the chisquared distribution. The relationship in Equation (70) forms the basis for the test,

χ n2−1 =

(n − 1)s 2

σ2

(70)

.

Wackerly, Mendenhall, and Scheaffer (2002) sketched out a proof of this equation, and
Penn State University (2015) provided more details of the proof. In this equation, n
represents the sample size and s the sample standard deviation. The chi-squared
distribution parameter is the degrees of freedom, n – 1. Because the definition of sample
variance is,

s2 =

∑ (x

i

− x)2

i

n −1
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,

Equation 68 simplifies to,

χ n2 −1 =

∑ (x − x )
i

i

σ

2

2

=

SS

σ

2

.

For a given sample size and probability, this value of χ 2n −1 can be used to calculate the
effect size which would be the difference between the variance needed to meet the PCI

(72)
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requirement and the maximum value from the sample that yielded a χ2 larger than the
statistic based on the desired significance and the value of the sample mean.
Before addressing power, the implications of Type I and Type II errors need
clarification for medical devices. It is important to remember that PCIs are calculated
using the inverse of the standard deviation. Smaller values of σ result in higher index
values. In comparing variances, three different hypothesis tests are possible.
Table 1
Hypothesis Tests for the Variance
Test Type

Hypotheses

Two-tailed

H 0 : σ 2 = σ 02 , H 1 : σ 2 ≠ σ 02

One-tailed, lower

H 0 : σ 2 ≤ σ 02 , H 1 : σ 2 > σ 02

One-tailed, upper

H 0 : σ 2 ≥ σ 02 , H 1 : σ 2 < σ 02

In the case of a Type I error for the two-tailed test, resource waste and delays in
the introduction of a device could occur while time is spent fixing a process that is not
broken. A Type II error could result in actions that would endanger patient wellbeing by
allowing a product that does not meet a specification to enter the marketplace. For the
one-tailed, lower test, the same error ramifications would hold. For the one-tailed, upper
test, reverse the results. In this case, a Type I error could endanger patient safety, and a
Type II error could lead to resource waste and unnecessary delays.
Much hypothesis testing of capability indices in the medical field examines the
one-tailed, lower case for the capability index that is the index less than a predetermined
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value. Because the basis of the index calculation is the reciprocal of the standard
deviation, the corresponding variance test is the one-tailed upper test. The emphasis is on
maximizing patient safety, so the testing focuses on whether or not the standard deviation
or variance exceeds that for an acceptable value of the capability index. If the standard
deviation exceeds the limit, the value of the index will be smaller than the target. To
achieve a balance between safety and wasted resources, α and β in this study use the same
value, 0.05.
Mathew’s (2010, p. 60) equation was used to determine the sample size. The
value of the sample variance at the critical χ 2 point is derivable from Equation 68,

χ n2−1 =

(n − 1)s 2

σ2

(73)

.

If σ = σ0 represents the variance of a sample distribution of s2 for H0, and σ1 represents the
values of σ under H1, then at the point where the chi-squared values are equal,

χ12−α , n −1σ 02
n −1

=

χ β2 ,n −1σ 12
n −1

.

(74)

Rearranging this expression yields,

χ12−α ,n−1 σ 12
=
.
χ β2 ,n−1 σ 02

(75)

One solves Equation 73 iteratively to find the value of n, the sample size, for
which it is true. Iteration is one of the methods suggested by Guenther (1965), Mathews
(2010), and Zar (2014). It does make sample size calculations impossible until the values
of σ1 are calculated using simulation or available data. Confidence intervals for the
variance come directly from Equation 74 (Mathews, 2010, p 58)
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The contents of this section included specifics addressing effect size, power
calculations, and sample size through the examination of hypothesis testing for variances.
These are closely related to hypothesis testing for capability indices but are more direct
because the values of the direct comparison of the variances. The section contains an
explanation of the theory for the comparison of PCIs while avoiding the additional
complexity that inverses and numerators unequal to one would introduce. A later section
contains an explanation of the application of these methods to the indices.

Procedures for Simulated Data Generation
I generated 12 different sets of data with the random number generators in R
(2016). Each set of data has three components. Fifty percent of the data, 5,000 points,
come from a normal distribution. Twenty-five percent of the data, 2,500 points, come
from an alternative distribution with its median located above the mean of the normal
distribution. The other 25% of the data come from an alternative distribution with its
median located below the mean of the normal distribution. The alternative distributions
are the gamma, lognormal, and Weibull.
I selected the gamma distribution because of its use in several studies on PCIs.
Ahmad, Abdollhian, and Zeephongsekul (2008) chose the gamma distribution to expand
the work of previous authors who used it (Liu & Chen, 2006; Tang & Than, 1999).
Chang and Bai (2001) selected it for their development of weighted variance control
charts. Derya and Canan (2012) also used it in control chart development.
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George and Ramachandran (2011) used it to explore the Johnson transform.
Hosseinifard et al. (2009) also used it to examine transformations. Pal (2005) generated a
nonnormal data set with the gamma distribution to evaluate PCI development using the
generalized lambda distribution. Rivera et al. (1995) selected it to generate data for
evaluation of several transformation methods.
I selected the Weibull distribution because of its widespread use in reliability
studies, and the lognormal distribution because it often results when output characterized
by several different distributions is combined (Ott, Schilling, & Neubauer, 2000). This
distribution is appropriate because one of the goals for this study was to examine the
effect on PCIs of a mixture of components from several distributions representing the
same mixing that might occur in upstream processes. The inclusion of the lognormal
distribution allows for this possibility.
Table 2 is an illustration of the generation of the component distributions. Table 3
is an illustration of the method of combining them.
Table 2
Composition of Study Simulated Data
ID

Title

Description
Central Distributions

A

nAtT

Normal distribution, µ at target = 100, σ = 5

B

nAtO

Normal distribution, µ offset left 1σ, σ = 5
(continued)
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ID

Title

Description
Lateral Gamma Distributions

C

gammaUpperT

Gamma distribution, shape = 100, rate = 1, median
transposed 1.5 σ to the right of the target.

D

gammaLowerT

Gamma distribution, shape =100, rate =1, reversed,
median transposed 1.5 σ to the left of the target.

E

gammaUpperO

Gamma distribution, shape = 100, rate = 1, median
transposed 2.5σ to the right of the target.

F

gammaLowerO

Gamma distribution, shape =100, rate =1, reversed,
median transposed 2.5 σ to the left of the target.

Lateral Lognormal Distributions
G

lognormalUpperT

Lognormal distribution, generated as indicated in
note, median transposed 1.5 σ to the right of the
target.

H

lognormalLowerT

Lognormal distribution, generated as indicated in
note, reversed, median transposed 1.5 σ to the left of
the target.

I

lognormalUpperO

Lognormal distribution, generated as indicated in
note, median transposed 2.5σ to the right of the
target.

J

lognormalLowerO

Lognormal distribution, generated as indicated in
note, reversed, median transposed 2.5 σ to the left of
the target.

Lateral Weibull Distributions
K

weibUpperT

Weibull distribution, shape = 10, scale = 10,
reversed, median transposed 1.5 σ to the right of the
target.

L

weibLowerT

Weibull distribution, shape = 10, scale = 10, median
transposed 1.5 σ to the left of the target.
(continued)

83
ID

Title

Description

M

weibUpperO

Weibull distribution, shape = 10, scale = 10,
reversed, median transposed 2.5σ to the right of the
target.

N

weibLowerO

Weibull distribution, shape = 10, scale = 10, median
transposed 2.5 σ to the left of the target.

Note. All data trimmed at the LSL and USL. Trimming occurs after transposition of the
lateral distributions. Trimmed data replaced by sampling with replacement from the
trimmed distribution until the number of data points equals the pre-trimmed number. For
gamma distribution random number generation, R (2016) uses rate as a simulation
parameter. Rate defined as 1/Scale. Lognormal values generated by taking µ = 92.5, and
σ = [log (107.5) – log (77.5)]/6, that is, determining a value based on the premise that
USL – LSL = 10σ. The Weibull is a left-tailed distribution, therefore, unlike the gamma
and lognormal, the upper distributions, rather than the lower, have reversed positions.
Table 3
Formation of Combined Distributions from Underlying Normal and Lateral
Distributions.
Formation of Offset Distributions
offsetDistributions1 = gammaUpperT + gammaLowerT
offsetDistributions2 = gammaUpperO + gammaLowerO
offsetDistributions3 = lognormalUpperT + lognormalLowerT
offsetDistributions4 = lognormalUpperO + lognormalLowerO
offsetDistributions5 = weibUpperT + weibLowerT
offsetDistributions6 = weibUpperO + weibLowerO
Formation of Combination Distributions
combinationDistribution1 = nAtT + offsetDistributions1
combinationDistribution2 = nAtO + offsetDistributions1
(continued)
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combinationDistribution3 = nAtT + offsetDistributions2
combinationDistribution4 = nAtO + offsetDistributions2
combinationDistribution5 = nAtT + offsetDistributions3
combinationDistribution6 = nAtO + offsetDistributions3
combinationDistribution7 = nAtT + offsetDistributions4
combinationDistribution8 = nAtO + offsetDistributions4
combinationDistribution9 = nAtT + offsetDistributions5
combinationDistribution10 = nAtO + offsetDistributions5
combinationDistribution11 = nAtT + offsetDistributions6
combinationDistribution12 = nAtO + offsetDistributions6
The first group of data consists of a normal distribution with its mean centered at
the target value with specification limits located five standard deviations on either side of
the mean. Using their medians, alternative distributions are located first at 1.5 standard
deviations on either side of the mean, followed by locations at 2.5 standard deviations on
either side of the mean. This relocation of data is a standard method in simulation studies
(Law, 2007).
The application of a simple linear transformation reversed the values to the left of
the target for the gamma and lognormal distributions, and to the right of the target for the
Weibull distribution, so that the tail of the distribution exhibits skew away from the
mean. This reversal imitates the real-world situation of distribution tails often pointing in
the least favorable direction and the scarcity of left tailed probability distributions
(Sleeper, 2007). The application of a custom R (2016) function truncated the values from
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the alternate distributions at a value equal to the LSL and USL. Such truncation is
common in simulation studies (Law, 2007). For example, truncated data results if, upon
inspection of process output, the quality department rejected all units with a value above
or below a quality limit (Nadarajah & Kotz, 2006; Plansky, Chou, & Mason, 1998).
Figure 6 shows the process of generating a combined distribution.

Figure 6. An illustration of combined distribution generation.
The second sample group is similar to the first, but with the normal and alternate
distributions locations shifted one standard deviation to the left of the target value. This
shift results in a less capable process, and the intent was to see how accurately the
process capability calculations reflects this. Using weighted probability values, accurate
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calculations yielded the equivalent capability indices. These are the standards of
comparison for the calculated values.
Along with multimodality, each distribution exhibits fat tails. This characteristic
may affect the required sample size needed to make accurate projections about the
features of the distribution (Wilcox, 2012). Each combination distribution is obviously
multimodal. Application of R (2016) functions transformed each distribution with the
Box-Cox, square root, inverse, inverse square root, and asinh (Rivera, 1995) transforms.
The application of normality tests determined if the results of the transformation are
beneficial. Results from the transformations indicated that normality is unachievable for
two distributions and evaluation required an alternative method.
I collected data from each distribution with the R sample function. Sampling
occurred without replacement. This replicated a situation in which destructive testing
occurs, for example, conducting a pull test to a joint failure.

Instrumentation and Operationalization of Constructs
Data collection in this study does not require instrument use. Computer simulation
generated all data. The data represents the value of a quality test performed on the output
of a process. The distributions of this test data, rather than the data themselves are the
focus of this study. Because the test values come directly from the simulated data, no
operationalization of constructs was required.
While variables in this study are unitless, because the indices are unitless, in
actual applications of the methods used, the user would directly measure the variables.
For example, some breaking force measures are pounds, ounces, newtons, or dynes.
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Potential length measures are inches, feet, millimeters, centimeters, or meters.
Dimensionally, because a division occurs with a unit of measure divided by the same unit
of measure in the calculation of an index, the indices are unitless. Measurement directly
yields the units of interest, so no operationalization was required.

Data Analysis Plan
This section contains an identification of the software used for analysis, the data,
the research questions, and the analysis plan. The description of the analysis plan
includes the statistical tests used to test the hypotheses. It also contains a section on the
interpretation of test results.

Software
The software used for the analysis was R (2016). In addition to base R, the
analysis required the use of several R packages: AID (Dag, Asar, & Ilk, 2015), ggplot2
(Wickham, 2009), gridExtra (Auguie, 2016), MASS (Venables & Ripley, 2002),
moments (Komsta & Novomestky, 2015), and nortest (Gross & Ligges, 2015).

Data Cleaning and Screening
Computer simulation generates the data used in this study. The careful selection
of the distribution parameters eliminates the need for data cleaning or screening. This
negates the need for any further data modification prior to analysis.

Research Questions and Hypotheses
The quantitative research question of this research was how accurately does the
calculated value of Cpk, under the assumption of normality, reflect the actual probabilities
of nonconformance from simulated distributions representing the mixture of components
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from different upstream production batches in a subsequent process? This question
reflects the real-world situation in which a production line uses components from several
different lots. A PCI, as used in industry, is primarily a point value (Porter and Oakland,
1991). A quality manual or protocol may state that the Cpk value must be greater than
1.33, 1.50, or some other value. This question leads to three formal research questions.
The first series of tests involve the comparison of calculated values of the PCIs
based on samples taken from each distribution set to a required value.

Research Question 1: Do the PCIs calculated from samples of the combined
distributions meet the industry standard?
H01: PCIC ≥ 1.33,
Ha1: PCIC < 1.33.
Peña-Rodríguez (2013) suggests the value of 1.33. PCIC uses the calculated Cpk
from sample sizes at levels of 10, 30, 59, and a value determined from each of the 12
distributions using the method described by Mathews (2010). The data in all research
questions represents the test results from a test conducted after the testing of a component
assembled from parts. I tested the data for normality using the Anderson-Darling method.
When the test results indicate nonnomality, I transformed and retested it. The second
series of tests involve a comparison of the calculated positions on the x-axis of 4 standard
deviations, equivalent to a Cpk of 1.33 to the value calculated from the parameters of the
12 combined distributions and their transformed values when required.

Research Question 2: Do the values calculated from samples taken from a
combined distribution exceed the actual values required to meet the standard?
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H02: xpci ≥ xpdf,
Ha2: xpci < xpdf.
xpci is the x-axis value calculated from the required value of the PCI, and xpdf is the
value calculated directly from the combined probability density functions. The results of
this test should mirror those of research question 1, but show the percentage difference
between the actual and calculated values. The test schema included only raw data because
of the inability to transform to normality.
Previous tests have used the combined distributions. The third series of tests
tested the components of the combined distributions individually and comparing the PCI
calculated from these distributions with the standard Cpk of 1.33.

Research Question 3: Do the data values from the lateral distributions, isolated
from the underlying normal distributions, meet the industry standards?
H03: PCgamma ≥ 1.33,
Ha3: PCgamma < 1.33,
H03: PClognormal ≥ 1.33,
Ha3: PClognormal < 1.33,
H03: PCWeibull ≥ 1.33,
Ha3: PCWeibull < 1.33.
In these hypotheses, PCgamma is the Cpk calculated from the gamma distributions,
PClognormal is the Cpk calculated from the lognormal distributions, and PCWeibull is the Cpk
calculated from the Weibull distributions. These tests evaluate the suggestion that lots
constructed using different lots of components require individual tests. This individual

90
testing might compensate for the effect of a fattened tail on the value of the standard
deviation used to calculate the capability index. Test input consists of both raw and
transformed data.
The operationalization of the above RQ into a null and alternative hypothesis
required the calculation of the PCIs from sample sizes of 10, 30, 59, and a sample size
needed to achieve an a priori specified power 1-beta. The value of 10 represents a low
convenience value. The value of 30 is key because it is the value at which a t-distribution
begins to correspond to a normal distribution. The sample size of 59 achieves a 95% level
of confidence (Lipson & Sheth, 1973). The calculated sample size based on power was
indeterminate until the generation of simulated results. The calculated sample size based
on power was indeterminate until the generation of simulated results.
Next, data from these samples permitted the calculation of a 95% confidence
interval for the PCIs. Because simulated data generates the entire populations, it was
possible to compute the true value of all of the capability indices. Finally, if PCIC
represents the calculated PCI, and PCIT represents the true index, then the hypothesis
tests operationalizing the above RQ was:
H0: PCIC ≥PCIT or required
Ha: PCIC < PCIT or required
My testing used methods for the variance/standard deviation and the chi-square
distributions and determined if the calculated PCI is greater than or equal to the true PCI.
This testing examined if a Type II error was occurring in the calculation of the PCI. The
definitional equation for Cpk was the basis for calculating the values for the sample PCIs.
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Next, does the calculation of actual values of the indices agree with the probabilities as
defined by the generating cumulative distribution function? From the definitional
equation for Cpk, it is readily apparent that the value of the index is directly proportional
to the distance between the mean of the samples and the specification limit, and inversely
proportional to the standard deviation of the sample. This establishes cause and effect of
the data on the value of the PCI.

Data Analysis Procedures
Structure of analysis. Hypothesis testing for variances and standard deviations to
give theoretical foundation for the tests outlined in this section. Those methods apply to
the testing of capability indices, but require an adjustment because capability indices rely
on the inverse of the standard deviation. Thus, if A < B < C is true, then, when inverses
are considered, the expression becomes, 1/C < 1/B < 1/A. Given the inverse relations of
the definitional equations, the larger the variances/standard deviations, the smaller the
capability indices are.
Figure 7 is a schematic representation of the analysis plan.
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Figure 7. Schematic representation of the data analysis plan.
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Confidence intervals. This study requires the calculation of PCIs from samples
drawn from the simulated output of a process described earlier. The underlying
assumption is that the process is under control and that whatever test performed on the
output from that process, for example, measuring fill weight of a container, will produce
normally distributed results. The assumption of normality is critical to hypothesis testing
of capability indices. In the case of the simulated data, testing confirmed or denied the
assumption of normality, but the calculation of the indices proceeded even if the results
from the raw data indicated nonnormality. This compromise allowed a comparison of the
conclusions drawn from an unwarranted assumption of normality to those based on
reality.
Consider first Equation 1 for Cp (repeated unnumbered for convenience),
Cp =

USL − LSL
.
6σ

If given a required value of Cp, and values for USL and LSL, the maximum value of σ that
will result in this value of Cp can be calculated from this expression as,

σ=

USL − LSL
.
6C p

If σ is larger than this value, the value of Cp is less than required.
Now, consider Equation 2 (repeated unnumbered for convenience),
 µ − LSL USL − µ 
C pk = Min 
,
.
3σ 
 3σ

(77)
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In this expression, for a given σ, the calculation of the value of Cpk uses the smaller of the
two values, μ – LSL or USL – μ. The smaller of the two uses the nearest specification
limit or NSL. The expression for Cpk then becomes,
C pk =

NSL
.
3σ

(78)

As was done for Cp, the maximum value of σ that gives the required value of Cpk is,

σ=

NSL
.
3C pk

(79)

The comparison of these values of the standard deviations to those calculated for each
simulated data set, for both raw and transformed data, uses the confidence intervals
calculated from the sample data.

Hypothesis testing, general. The research question in this study was, given that
the value of a process capability, calculated from a set of data composed of the
combination of values from three different distributions, does that index adequately
reflect the overall capability of the process? Answering the research question requires
three different sets of hypothesis tests.

Hypothesis tests against the requirement. This series of tests calculated the
values of the PCIs using samples taken from each distribution set and tested them against
a desired value. The value is 1.33 as suggested by Peña-Rodríguez (2013). If PCIT
represents the calculated capability index, that is, either Cp or Cpk, the hypothesis test
was:
H01: PCIC ≥ 1.33,
Ha1: PCIC < 1.33.
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These tests included data from all 12 distributions.

Hypothesis tests against the calculated value. Because the combined
distributions were constructed using probability distributions with known parameters, a
capability index of 1.33 determines an exact x-axis value. This series of tests compared
the x-axis values of the PCIs calculated using samples taken from each distribution set
against that value. If the value calculated directly from the probability density functions is
xpdf, and the value for the capability indices is xpci, then the hypothesis test becomes,
H02: xpci ≥ xpdf,
Ha2: xpci < xpdf.
Tests included data from all 12 distributions.

Hypothesis tests with components from each distribution taken separately.
Combining the three distributions fattened the tails of the majority normally distributed
data and increased the value of the standard deviation. This series of tests individually
addressed data for the gamma, lognormal, and Weibull distribution placed to the left of
the mean of the normal distribution. It was not necessary to test the normal distribution or
the other distribution located to the right of the mean of the normal distribution. Because
of their construction, these distributions would yield a capable process. The testing
concludes with comparisons of the calculated capability index values to the standard of
1.33. Representing these capability indices by PCgamma, PClognormal, and PCWeibull, the
hypothesis tests become,
H03: PCgamma ≥ 1.33,
Ha3: PCgamma < 1.33,
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H03: PClognormal ≥ 1.33,
Ha3: PClognormal < 1.33,
H03: PCWeibull ≥ 1.33,
Ha3: PCWeibull < 1.33.
These tests evaluate the suggestion that lots constructed using different lots of
components require individual tests. This individual testing might compensate for the
effect of a fattened tail on the value of the standard deviation used to calculate the
capability index.

Threats to Validity
This section contains a discussion of external, internal, construct validity, and
ethical considerations. In the extensive literature review conducted for this study, the
mathematical nature of the research was paramount, and no concerns about validity arose
except those arising from the possible lack of process control or nonnormality of the data.
This nonnormality condition was the focus of this study.

External Validity
All analysis in this study uses definitional equations and simulated data. Because
of this, the results do not tie to any particular period, product, or process. The FDA
requirement for lot traceability of components used in the manufacture of
pharmaceuticals and medical devices led to the choice of the medical device
manufacturing segment as the setting for this study. This requirement guarantees that the
information to separate components by production lot is available. The results of this
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study would be generalizable to any scenario in which information from component lots
is accessible. There are no anticipated external threats to validity.
Simulations consisted of 10,000 data points. This is a commonly used number in
simulation studies; for example, it is the number used by English and Taylor (1993), Han
(2006), and Hosseinifard and Abbasi (2009). Whether or not this number is appropriate
would depend on the medical device manufactured. In the case of hypodermic syringes,
where worldwide daily production would number in the millions of units per day, it
might be small. In the case of M.R.I. machines, where the total number of machines in
existence worldwide is only 36,000 (Rinck, 2016), it might be too large. However, it was
large enough to determine if the overall approach taken in this study is valid, but might
require some adjustment under specific, large-scale application of the methodology.
This study was very specific in its limitations, that is, cases where traceable lots
from upstream processes are mixed. The test results of the testable product made from
those components are separable by lot. In other cases, the method may not be applicable.

Internal Validity
All analysis in this study uses definitional equations and simulated data. There are
no human or animal subjects involved. Because of the lack of subjects who can react or
adjust to the research, there are no anticipated internal threats to validity.

Construct Validity
Construct validity refers to whether an instrument actually measures what it was
constructed to measure. Historically, it was a general category for all validity (Warner,
2008). It is in this sense that the following discussion takes place.
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One area of this study that might raise questions is trimming the simulated data to
eliminate any points laying outside of 5 standard deviations and replacing the trimmed
data with new points drawn from the remaining distribution using the sampling procedure
in R (2015). Sleeper (2007) cautioned “Truncation is usually the wrong way to solve a
modeling problem” (p. 50). His point is valid if the raw process is considered. In contrast,
this study is examining components that have already gone through a sorting process by a
quality control department and the truncation and replacement that would take place to
achieve a full lot size reflects reality (Nadarajah & Kotz, 2006; Plansky et al., 1998).
Truncating a distribution does change the nature of the distribution. Consider the
standard normal distribution for simplicity’s sake. Figure 8 contains an illustration of a
comparison of the CDF of a truncated distribution (assuming upper and lower control
limits of ±1.64, with the upper and lower 5% eliminated).
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Figure 8. Comparison of a trimmed and non-trimmed CDF of a normal function.
The trimmed distribution begins later than the non-trimmed distribution because
of the truncation, crosses at the mean, and then increases more rapidly. In addition, the
truncated distribution boundaries are ± 1.64, while the nontruncated distribution’s domain
is ± ∞.
Another area of construct validity that might arise was the use of Cpk itself as a
standard for judging the performance of a process. This also could overlap into the realm
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of face validity. As several authors cited in this study have pointed out, this is a valid
question. However, Cpk has become the standard and a goal of this study was to help
evaluate its suitability for that task.
The validity of the conclusions of this study might be subject to some scrutiny
under the new examination of the use of p-values in research by the American Statistical
Association (Wasserstein & Lazar, 2016). Any judgment as to the suitability of p-values
in research lies far out of the scope of this study.

Ethical Procedures
This study was a purely quantitative comparative research in mathematical
modeling and simulation. Computer simulation generates all data specifically for this
study. Values for the initial target value are set as 100 for ease of computation and to aid
in the understanding and visualization of differences in the values. Setting this value at
100 makes it easier to think in terms of the target being 100%. This resemblance may
also aid understanding. The upper and lower specification limits are set as being
equivalent to five standard deviations because this would correspond to plus or minus
25% of the target value while also allowing a five-unit transposition of the mean to still
fall within the specification limits. Parameter values of the lateral distributions are set as
typical values that would give these distributions their characteristic shapes.
No human or animal participants are involved. There are no anticipated
requirements for the use of confidential information; therefore, there are no storage,
anonymity, or privacy issues. This study used no corporate data or equipment. The
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Walden Institutional Review Board (IRB) approval number for this study is 11-16-160029746.

Summary
This chapter contains a summary of the methodology, including the population
studied, mathematical model construction, sampling techniques, and statistical tests.
Model construction combines a normal central distribution, and two noncentral
distributions. The noncentral distributions were the gamma, the lognormal, and the
Weibull distributions. The location of the median of the noncentral distributions is one
and a half standard deviations to the left of the mean of the central distribution. Reversal
of the left noncentral distribution yields left pointing tails. Combining the distributions
fattened the tails of the overall distribution.
The research included two cases of the combined distributions. The first cases
assumed that the target value of the distribution is the mean of the central distribution.
The second case offset the central distribution and the two noncentral distributions to the
left of the mean of the original central distribution by one standard deviation. In both
instances, the mean of the original, non-offset, central distribution was the target of the
distribution.
There is an infinite number of distributions, combinations of distributions, and
offsets possible. The methods of analysis developed for this study are not unique to those
selected, and are adaptable to other combinations of distributions. The concern was to
simulate subcomponents, with different physical characteristics, from different lots
combined in a downstream production process in the manufacture of medical devices or
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pharmaceutical products. The research requires the application of a series of hypothesis
tests, designed to measure the effects of lot mixing on the most commonly used measures
of the process capability of the final process.
The next chapter contains a description of the individual and combination
distributions developed for this study, as well as the results of the hypothesis tests
performed on a series of samples taken from the distributions.
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Chapter 4: Results

Introduction
The purpose of this empirical quantitative study was to develop a framework that
evaluates the ability of a PCI to accurately measure medical device test data under a
scenario where output data combines the effects of mixed production lots of components
in the medical device industry. Computer simulation generated twelve different sets of
data representing mixed production test results where subcomponents came from
different production lots. Testing of the sampled data used an industry standard PCI, Cpk,
to determine if the test results reflected the actual process capability by answering several
research questions.

Research Question 1: Do the PCIs calculated from samples of the combined
distributions meet or exceed the industry standard of 1.33?

Research Question 2: Do the values calculated from samples taken from a
combined distribution exceed the actual values required to meet the industry standard?

Research Question 3: Do the data values from the lateral distributions, isolated
from the underlying normal distributions, meet the industry standard?
This chapter begins with a description of the equivalent of a pilot study for this
type of research. Next, it moves to the timing and methods used to generate the data.
Following this is a description of the data generated, the rationale behind the statistical
methods used for analysis, the results of the data analysis, including power and effect
sizes, and the outcomes of the hypothesis tests formulated to answer the research
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questions. The chapter concludes with summary of the results from the analysis and the
research questions.

Data Generation
Background
From the conceptual stage of the development of this study, the intent was to use
computer simulated data. There are three key reasons for this. First, gaining approval for
the use of actual data would be difficult because the purpose of the study is to examine
data on the boundaries of those which would yield acceptable results for examining the
production of a medical device. Given the litigious nature of our society, securing
permission to use questionable data would be difficult.
The second reason is the difficulty in producing data specifically for use in this
study. The research investigates 12 different data sets with 10,000 points in each set. The
time and expense involved in generating this quantity of information is prohibitive.
Last, the simulated data allow the exact characterization of each of the frequency
distributions generated. This precision permits the precise comparison of the results of
the statistical analyses with known information for each distribution. The result is an
exact answer to RQ 3.
Development of the programs used to analyze the data began prior the time that
the prospectus received approval. Final generation of the computer simulated data did not
occur until after IRB approval of this study. Through the use of a different random seed,
the data for this study is different than that used to develop the program.
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Data Generation Procedure
The generation of the simulated data followed the procedures listed in Tables 2
and 3. The rgamma, rnorm, and rweibull random number generators in the base R (2016)
package generated the random numbers using the parameters listed in Table 2.
Generating the random numbers using these functions is straightforward.
Generating the lognormal random numbers requires first creating a series of
random numbers using rnorm. These random numbers corresponded to the logarithms
centered at the value of the mean of the distribution with a standard deviation equivalent
to the value of the log of the upper tolerance limit minus the lower tolerance limit divided
by 10. The subtraction operation is not division in this case, even though it involves
logarithms. Nor does the division by 10 represent finding a root. Instead these operations
divide up the x-axis to find the standard deviation. In the lognormal distribution, it is the
logarithms of the data values that are normally distributed. The actual data values come
from raising e to the powers generated with these steps.
Combinations of data generated from the R (2016) random number generators
formed 12 different distributions. The details of the combinations are in Table 3.
Application of the R sample function provided sample sizes of 10, 30, and 59 data values
with an additional value calculated for each distribution based on the standard deviation
of the distribution sampled.
The data represent the results of a quantifiable test applied to a component made
up of subcomponents from three identifiable lots. This situation occurs in medical device
manufacturing because of the FDA requirement for lot traceability. While an infinite
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number of distributions of test results would arise in the real world, the methods
developed in this research are applicable to any fat tailed distributions and are not limited
to the data generated for this research.
Histograms of the data from the 12 combination distributions are in Appendix A.
In Figure A1, nAtT is the underlying normal distribution used with the lateral
distributions. Figure A2, nAtO, is the offset normal distribution used with the lateral
distributions. The R (2016) code to generate the data is in the file
DCode03_Simulations.r located in Appendix B.

Study Results
Descriptive Statistics
Table 4 provides a summary of the descriptive statistics for the 12 combination
distributions. Each distribution contains 10,000 data points. The column labeled Sample
Size is the calculated sample size used in the data analysis along with the values of 10,
30, and 59. I used the method found in Mathews (2010) for this calculation. Skew and
kurtosis functions are not part of the base R (2016) package. The moments package
(Komsta & Novomestky, 2015) furnishes these functions.
Note that two of the calculated sample sizes are size 10. The analysis results from
values that duplicate those of the chosen sample size of 10. While elimination of the
results from the calculated sample size of 10 avoids repetition, keeping them facilitates
any comparisons of the results of the calculated sizes.
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Table 4
Summary Statistics of Combination Distributions

Standard
Deviation
8.68

Skew
-0.02

Kurtosis
3.42

Calculated
Sample
Size
16

Distribution
comboDist1

Mean
100.01

Median
100.05

comboDist2

97.51

96.52

9.00

0.50

3.36

14

comboDist3

99.19

99.68

10.80

-0.08

2.77

9

comboDist4

96.69

95.54

10.87

0.45

2.88

9

comboDist5

100.06

100.09

6.77

-0.02

2.07

48

comboDist6

97.56

95.90

7.20

0.40

2.25

34

comboDist7

97.57

100.05

10.11

-0.52

2.05

10

comboDist8

95.07

95.09

9.78

-0.01

1.93

11

comboDist9

99.04

99.44

9.14

-0.07

3.27

13

comboDist10

96.54

95.70

9.18

0.48

3.45

13

comboDist11

97.56

98.97

10.69

-0.18

2.63

9

comboDist12

95.06

94.76

10.39

0.36

2.95

10

Preliminary Steps
I drew samples of each sample size for analysis using the sample function in R
(2016) and used the ad.test function from the nortest package to test for normality. The
ad.test uses the Anderson Darling test (Gross & Ligges, 2015). This test is particularly
sensitive to the tails of a distribution. Because the distributions created for this study
purposely have heavy tails, the Anderson Darling test would provide the strictest results.
Table 5 contains the results of the Anderson Darling test for all of the samples
from the different distributions. The column labeled AD Statistic has the Anderson
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Darling statistics for the distributions, and p Value is the associated p value. In the case of
the Anderson Darling statistic, smaller is better. Values of p less than .05 indicate that the
test failed to show normality. The p values have 3 decimal places to clearly illustrate the
failures.
Table 5
Anderson Darling Test Results with Failures in Bold Font
Distribution
Dist1SampSize10

AD Statistic
0.36

p Value
.368

Dist1SampSize30

0.25

.725

Dist1SampSizeC16

0.31

.527

Dist1SampSize59

0.16

.946

Dist2SampSize10

0.24

.689

Dist2SampSize30

0.28

.605

Dist2SampSizeC14

0.26

.638

Dist2SampSize59

0.31

.546

Dist3SampSize10

0.26

.624

Dist3SampSize30

0.42

.306

Dist3SampSizeC9

0.27

.581

Dist3SampSize59

0.27

.668

Dist4SampSize10

0.24

.684

Dist4SampSize30

0.64

.084

Dist4SampSizeC9

0.22

.756

Dist4SampSize59

0.32

.529
(continued)
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Distribution
Dist5SampSize10

AD Statistic
0.22

p Value
.762

Dist5SampSize30

0.21

.853

Dist5SampSizeC48

0.57

.134

Dist5SampSize59

0.58

.128

Dist6SampSize10

0.12

.985

Dist6SampSize30

0.39

.365

Dist6SampSizeC34

0.64

.087

Dist6SampSize59

0.71

.062

Dist7SampSize10

0.42

.259

Dist7SampSize30

0.59

.114

Dist7SampSizeC10

0.42

.259

Dist7SampSize59

1.86

.000

Dist8SampSize10

0.25

.669

Dist8SampSize30

0.26

.679

Dist8SampSizeC11

0.26

.631

Dist8SampSize59

0.75

.048

Dist9SampSize10

0.19

.868

Dist9SampSize30

0.25

.719

Dist9SampSizeC13

0.22

.794

Dist9SampSize59

0.32

.517
(continued)
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Distribution
Dist10SampSize10

AD Statistic
0.26

p Value
.616

Dist10SampSize30

0.37

.400

Dist10SampSizeC13

0.40

.306

Dist10SampSize59

0.22

.833

Dist11SampSize10

0.25

.651

Dist11SampSize30

0.41

.320

Dist11SampSizeC9

0.33

.435

Dist11SampSize59

0.68

.074

Dist12SampSize10

0.30

.524

Dist12SampSize30

0.21

.856

Dist12SampSizeC10

0.30

.524

Dist12SampSize59

0.36

.439

Only two datasets failed the normality test; both data sets had the largest sample
size, 59, and the lognormal lateral distribution. I next transformed the data identified as
nonnormal using the Box-Cox, square root, inverse, inverse square root, and asinh
transforms. A Box-Cox transformation function is not part of the base R (2016) package
but is in the AID package (Dag, Asar, & Ilk, 2015). The boxcoxnc function applies a
sequence of lambda value to the transform and then tests for normality using seven
different normality tests, including the Anderson Darling test.
Table 6 contains the transformation results. The p values have 3 decimal places to
clearly illustrate the failures. None of the transformation methods succeeded. Because
one of the purposes of this study to examine the results a statistically unsophisticated
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engineer might generate, the nonnormal data will remain part of the analysis.
Statistically, this is incorrect practice. The engineer should adjust the process to achieve
normal output, or output transformable to normality.
Table 6
Anderson Darling Normality Test Results of Transformed Nonnormal Data
Dist7SampSize59

Dist8SampSize59

Method

AD Statistic

p Value

AD Statistic

Box-Cox

0.96

.015

0.75

p
Value
.047

Square Root

2.03

.000

0.76

.045

Inverse

2.61

.000

0.89

.021

Inverse Square Root

2.41

.000

0.83

.030

Asinh

2.21

.000

0.79

.039

Statistical Assumptions
Normality of data was the underlying assumption behind this study. PCI
calculation depends on this assumption. The analytical tool used to answer RQ1, using
the chi squared distribution to compare two variances, also depends on normality of data.
The testing for normality using the Anderson Darling test showed the validity of this
assumption for all but two of the distributions. Attempts to transform these distributions
to normality failed, but the analysis continued as if normality was present for reasons
explained in the previous section.
RQ2 and RQ3 were deterministic with results based on calculated numbers from
the distributions rather than through statistical analysis. Answering these questions
involved no statistical assumptions. The lack of statistical inference restricts the answers
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to these questions to the generated distributions, so generalization of the conclusions is
more difficult. Generalizing these answers requires careful qualification of the
applicability conditions.

Research Question 1
Research Question 1 was, do the PCIs calculated from samples of the combined
distributions meet the industry standard of 1.33.
H01: PCIC ≥ 1.33,
Ha1: PCIC < 1.33.
Answering RQ1 was a multiple stage process beginning with comparisons of
variance. Common tests for equality of variance do not apply because they depend on
values calculated from individual data points from two samples. These common tests
include the F-test (Sheskin, 2000), Levene’s (1960) test, etc. Sampling distributions of
variances follow a chi squared distribution. This forms the basis for answering this
research question.
The calculations for Dist1SampSize30 form an example. The mean of the data
from this distribution is 99.9460 and the pooled standard deviation is 8.6647. The
required standard deviation for a Cpk of 1.33 is the minimum of (99.9653 – 75) and (125 –
99.9653), where 75 and 125 are the lower and upper tolerance limits, divided by 4. For
this distribution, the required standard deviation is 6.2413. The standard deviations of
8.6637 and 6.24 correspond to variances of 75.0600 and 38.9376 respectively.
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The variances provide the basis for calculating the confidence intervals for the
respective standard deviations and Cpk values. The relationship used to do the calculations
is found in Zar (2014, p. 127),

χ2 =

vs 2

σ2

,

(80)

where v is the degrees of freedom, s is the sample standard deviation, and σ is the
standard deviation under study. The process begins with calculating the chi squared
values corresponding to the probability density function values. Figure 9 is a plot of chi
squared values with the value at the 95% confidence value indicated by a solid line.
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Figure 9. Chi squared values for a distribution with nine degrees of freedom.
Algebraic manipulation of Equation 80 yields the relation needed to calculate
confidence intervals for the variance. The relationship for the variances is in Equation 81.
Figure 10 contains a plot of the variance values with confidence interval indicated. The
plot is for a standard deviation of 6.2413. This is the standard deviation needed to result
in a Cpk of 1.33 when the mean is 99.9653 for Dist1SampSize30, that is, the value of the
mean for Dist1SampSize30.

vs 2

χ 2α /2,v

<σ2 <

vs 2

χ 21−α / 2,v

.

(81)
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Proper understanding of Figure 10 is critical to the understanding of the analysis
in this study. Unless a variance lies to the right of the 95% boundary, it cannot be
concluded that it is larger than the variance it is being compared to, If the test variance
lies to the left of the dotted line, the null hypothesis that it is less than or equal to the
comparison variance is accepted. If the formulation of the null hypothesis was the Cpk
values were less than 1.33, then the lower 5% boundary is applicable.

Figure 10. Distribution of the variance for Dist1SampSize30.
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Taking the square root of Equation 81 gives the relationship for the standard
deviation. Figure 11 contains an illustration of the transformation from variance to
standard deviation with the 95% confidence value indicated by a dotted line.

Figure 11. Distribution of the standard deviation.
The value of Cpk is a transformation of the value of the standard deviation. Further
manipulation of Equation 81 gives the confidence limits for Cpk.

Interval
3

vs 2

χ

2

α / 2, v

<

Interval
Interval
<
,
3σ
vs 2
3 2

χ

1−α / 2, v

(82)
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where Interval is the smaller of the mean minus LTL, and UTL minus the mean. Figure
12 contains the results of the application of this transformation to the distribution of
standard deviations. This figure represents the distribution of Cpk values if

Dist1SampSize30 did have a Cpk value of 1.33. The 5% boundary moves from the left to
the right of the curve because the calculation of Cpk requires the use of the inverse of the
standard deviation.

Figure 12. Distribution of the Cpk values.
With the relationship between chi squared values and Cpk values established, this
relationship furnished the tool needed to evaluate if the Cpk values from the distribution
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differed from the 1.33 value at a statistically significant level. The program used to
generate the results for these calculations is in the file DCode21_RQ1.r in Appendix B.
The power of the result is determined by using Equation 83 (Zar, 2014, p. 130),


σ2 
1 − β = P  χ 2 ≥ χα2 ,v 20  ,
s 


(83)

where v is the degrees of freedom, σ 02 is the variance tested against, and s2 is the variance
being tested.
The use of the term effect size may be misleading in this study because of the lack
of any treatment. Assuming that whatever difference in parameters present in the
simulated test results and those need to achieve a Cpk of 1.33 constitute the treatment,
then the effect size can be calculated by adapting an equation from Grissom and Kim
(2012, p. 63),

∆G =

C pkR − C pkT

σT

.

(83)

In this equation, the Cpk values substitute for the mean values. The subscript, R, is the Cpk
value compared to the standard of 1.33 based on the standard deviation σT.
I calculated the one tailed 95% confidence interval for the Cpk s that would result
from the conditions necessary to achieve a value of 1.33. The last calculation was for the

p value for the results from the simulated data. Table 7 contains the results.
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Table 7

Results for Research Question 1. Nontransformable, Nonnormal Data in Bold Font

Distribution
Dist1SampSize10

Variance Test
Statistic Chi
Value
16.92

Tested
Variance Chi
Value
17.34

Variance 95%
Confidence
Limit
[39.87, ∞]

Equivalent Cpk
1.32

Dist1SampSize30

42.56

55.70

[50.98, ∞]

1.17

Dist1SampSizeC16

25.00

28.87

[45.03, ∞]

1.24

Dist1SampSize59

76.78

110.42

[56.06, ∞]

1.11

Dist2SampSize10

16.92

22.82

[42.44, ∞]

1.15

Dist2SampSize30

42.56

73.90

[54.72, ∞]

1.01

Dist2SampSizeC14

22.36

33.41

[47.00, ∞]

1.09

Dist2SampSize59

76.78

146.63

[60.61, ∞]

0.96

Dist3SampSize10

16.92

28.13

[60.50, ∞]

1.03

Dist3SampSize30

42.56

90.28

[78.02, ∞]

0.92

Dist3SampSizeC9

15.51

25.28

[59.26, ∞]

1.04

Dist3SampSize59

76.78

183.08

[87.38, ∞]

0.86

Dist4SampSize10

16.92

35.25

[60.89, ∞]

0.92

Dist4SampSize30

42.56

114.30

[79.38, ∞]

0.81

Dist4SampSizeC9

15.51

32.00

[60.05, ∞]

0.93

Dist4SampSize59

76.78

231.44

[88.91, ∞]

0.77
(continued)
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Distribution
Dist5SampSize10

Variance Test
Statistic Chi
Value
16.92

Tested
Variance Chi
Value
10.32

Variance 95%
Confidence
Limit
[23.73, ∞]

Equivalent Cpk
1.71

Dist5SampSize30

42.56

33.94

[30.92, ∞]

1.49

Dist5SampSizeC48

64.00

54.65

[33.21, ∞]

1.44

Dist5SampSize59

76.78

68.08

[34.48, ∞]

1.42

Dist6SampSize10

16.92

14.18

[26.63, ∞]

1.46

Dist6SampSize30

42.56

46.91

[35.14, ∞]

1.27

Dist6SampSizeC34

47.40

53.60

[35.83, ∞]

1.25

Dist6SampSize59

76.78

94.49

[39.17, ∞]

1.20

Dist7SampSize10

16.92

28.17

[53.15, ∞]

1.03

Dist7SampSize30

42.56

90.84

[68.40, ∞]

0.91

Dist7SampSizeC10

16.92

27.94

[52.84, ∞]

1.04

Dist7SampSize59

76.78

186.18

[77.15, ∞]

0.86

Dist8SampSize10

16.92

33.17

[49.48, ∞]

0.95

Dist8SampSize30

42.56

107.95

[64.26, ∞]

0.84

Dist8SampSizeC11

18.31

37.02

[51.00, ∞]

0.94

Dist8SampSize59

76.78

220.85

[72.43, ∞]

0.79

Dist9SampSize10

16.92

20.19

[43.01, ∞]

1.22

Dist9SampSize30

42.56

65.09

[55.53, ∞]

1.08

Dist9SampSizeC13

21.03

26.88

[46.03, ∞]

1.18

Dist9SampSize59

76.78

133.93

[62.78, ∞]

1.01
(continued)
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Distribution
Dist10SampSize10

Variance Test
Statistic Chi
Value
16.92

Tested
Variance Chi
Value
25.31

Variance 95%
Confidence
Limit
[43.24, ∞]

Equivalent Cpk
1.09

Dist10SampSize30

42.56

82.27

[56.33, ∞]

0.96

Dist10SampSizeC13

21.03

34.02

[46.57, ∞]

1.05

Dist10SampSize59

76.78

168.51

[63.44, ∞]

0.90

Dist11SampSize10

16.92

31.70

[59.90, ∞]

0.97

Dist11SampSize30

42.56

102.18

[76.89, ∞]

0.86

Dist11SampSizeC9

15.51

28.29

[58.05, ∞]

0.99

Dist11SampSize59

76.78

209.85

[86.46, ∞]

0.81

Dist12SampSize10

16.92

37.67

[56.27, ∞]

0.89

Dist12SampSize30

42.56

122.12

[72.64, ∞]

0.79

Dist12SampSizeC10

16.92

38.12

[56.47, ∞]

0.89

Dist12SampSize59

76.78

250.05

81.47

0.74

Table 8

Additional Results for Research Question 1. Nontransformable, Nonnormal Data in Bold
Font

Power

p Value

Effect Size

Dist1SampSize10

0.46

0.04

-0.06

Dist1SampSize30

0.81

0.00

-0.06

Dist1SampSizeC16

0.60

0.02

-0.06

Dist1SampSize59

0.96

0.00

-0.06

Distribution

(continued)
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Distribution

Power

p Value

Effect Size

Dist2SampSize10

0.67

0.01

-0.09

Dist2SampSize30

0.97

0.00

-0.09

Dist2SampSizeC14

0.80

0.00

-0.09

Dist2SampSize59

1.00

0.00

-0.09

Dist3SampSize10

0.80

0.00

-0.10

Dist3SampSize30

0.99

0.00

-0.09

Dist3SampSizeC9

0.77

0.00

-0.10

Dist3SampSize59

1.00

0.00

-0.10

Dist4SampSize10

0.89

0.00

-0.12

Dist4SampSize30

1.00

0.00

-0.12

Dist4SampSizeC9

0.87

0.00

-0.12

Dist4SampSize59

1.00

0.00

-0.12

Dist5SampSize10

0.10

0.33

-0.01

Dist5SampSize30

0.16

0.24

-0.02

Dist5SampSizeC48

0.20

0.21

-0.02

Dist5SampSize59

0.24

0.17

-0.02

Dist6SampSize10

0.29

0.12

-0.05

Dist6SampSize30

0.61

0.02

-0.05

Dist6SampSizeC34

0.66

0.01

-0.05

Dist6SampSize59

0.85

0.00

-0.05
(continued)
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Distribution

Power

p Value

Effect Size

Dist7SampSize10

0.80

0.00

-0.10

Dist7SampSize30

0.99

0.00

-0.10

Dist7SampSizeC10

0.79

0.00

-0.10

Dist7SampSize59

1.00

0.00

-0.10

Dist8SampSize10

0.87

0.00

-0.13

Dist8SampSize30

1.00

0.00

-0.13

Dist8SampSizeC11

0.89

0.00

-0.13

Dist8SampSize59

1.00

0.00

-0.13

Dist9SampSize10

0.58

0.02

-0.07

Dist9SampSize30

0.92

0.00

-0.07

Dist9SampSizeC13

0.67

0.01

-0.07

Dist9SampSize59

1.00

0.00

-0.08

Dist10SampSize10

0.74

0.00

-0.10

Dist10SampSize30

0.99

0.00

-0.10

Dist10SampSizeC13

0.83

0.00

-0.10

Dist10SampSize59

1.00

0.00

-0.10

Dist11SampSize10

0.85

0.00

-0.11

Dist11SampSize30

1.00

0.00

-0.11

Dist11SampSizeC9

0.82

0.00

-0.11

Dist11SampSize59

1.00

0.00

-0.11
(continued)
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Distribution

Power

p Value

Effect Size

Dist12SampSize10

0.91

0.00

-0.13

Dist12SampSize30

1.00

0.00

-0.14

Dist12SampSizeC10

0.91

0.00

-0.14

Dist12SampSize59

1.00

0.00

-0.14

Based on these results, I cannot reject the alternate hypothesis for the distributions
listed in Table 8. I cannot reject the null hypothesis for the distributions listed in Table 9.
Table 9

Distribution Failing to Meet the Null Hypothesis Condition.
Dist1SampSize30

Dist4SampSize59

Dist7SampSize30

Dist10SampSize59

Dist1SampSize59

Dist5SampSize30

Dist7SampSize59

Dist11SampSize30

(Dist2SampSize30

Dist5SampSizeC48

Dist8SampSize30

Dist11SampSize59

Dist2SampSize59

Dist5SampSize59

Dist8SampSize59

Dist12SampSize30

Dist3SampSize30

Dist6SampSize30

Dist9SampSize30

Dist12SampSize59

Dist3SampSize59

Dist6SampSizeC34

Dist9SampSize59

Dist4SampSize30

Dist6SampSize59

Dist10SampSize30

Note. Reject null hypothesis for listed distributions.
Table 10

Distributions Meeting the Null Hypothesis Condition.
Dist1SampSize10

Dist4SampSize10

Dist8SampSize10

Dist11SampSize10

Dist1SampSizeC16

Dist4SampSizeC9

Dist8SampSizeC11

Dist11SampSizeC9

Dist2SampSize10

Dist5SampSize10

Dist9SampSize10

Dist12SampSize10

Dist2SampSizeC14

Dist6SampSize10

Dist9SampSizeC13

Dist12SampSizeC10

Dist3SampSize10

Dist7SampSize10

Dist10SampSize10

Dist3SampSizeC9

Dist7SampSizeC10

Dist10SampSizeC13
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Note. Cannot reject null hypothesis for listed distributions.

Research Question 2
Research Question 2 was, do the values calculated from samples taken from a
combined distribution exceed the actual values required to meet the standard. While
stated as a hypothesis test, the answer comes from deterministic mathematical
calculations. The premise of the calculation of Cpk is that the possibility of a process
yielding a value outside of the tolerance limit is equal to the probability of a point falling
more than four standard deviations from the mean in a standard normal distribution.
Answering Research Question 2 determines how many points from the combination
distributions meet this criteria.
Determining the answer to this question begins by calculating the limits of the
distribution. The limits are the points laying beyond the intervals formed by taking the
mean plus four standard deviations, and the mean minus four standard deviations. The
number of points laying beyond these boundaries provides the answer to the question.
Verification of the results consisted of determining the empirical cumulative
distribution function (ecdf) for each of the 12 combination distributions. Determining if
any points of the ecdf fall outside of the probabilities of laying more than four standard
deviations from the mean answers the question. If no values lie outside of the tolerance
limits, then the process is still producing the desired output even if the Cpk value is below
1.33.
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Table 10 contains the results of this analysis. The “0” and “-Inf” entries indicate
that no values lay outside of the boundaries. Calculations are to four decimal points to
increase the clarity of the results.
Table 11

Results from Research Question 2
Max

Min

Proportion

Proportion

Low

High

Low

High

Points Points Value Value

Value

Value

Low
Distribution

High

comboDist1

0

0

-Inf

-Inf

0

0

comboDist2

0

0

-Inf

-Inf

0

0

comboDist3

0

0

-Inf

-Inf

0

0

comboDist4

0

0

-Inf

-Inf

0

0

comboDist5

0

0

-Inf

-Inf

0

0

comboDist6

0

0

-Inf

-Inf

0

0

comboDist7

0

0

-Inf

-Inf

0

0

comboDist8

0

0

-Inf

-Inf

0

0

comboDist9

0

0

-Inf

-Inf

0

0

comboDist10

0

0

-Inf

-Inf

0

0

comboDist11

0

0

-Inf

-Inf

0

0

comboDist12

0

0

-Inf

-Inf

0

0
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Table 12

Additional Results from Research Question 2.
Distribution

Min Value

Max Value

comboDist1

75.0205

124.8790

comboDist2

75.0205

124.8790

comboDist3

75.0228

124.9458

comboDist4

75.0228

124.9458

comboDist5

81.0589

118.9411

comboDist6

76.7805

118.9411

comboDist7

75.0253

118.9411

comboDist8

75.0253

118.9411

comboDist9

75.0007

124.9886

comboDist10

75.0007

124.9886

comboDist11

75.0003

124.9886

comboDist12

75.0003

124.9886

The calculations indicate that the process is producing no output beyond the
tolerance limits. Because the lateral distributions were trimmed, and the tolerance limit is
at least four standard deviations from the mean of the underlying distributions, this is not
an unexpected result. While not ideal results because of the lack of normality,
engineering time spent “fixing” these processes could take second place to higher
priorities.

Research Question 3
Research Question 3 was, do the data values from the lateral distributions,
isolated from the underlying normal distributions, meet the industry standard. While
stated as a hypothesis test, the answer comes from deterministic mathematical
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calculations. Input to answer this question included the mean of each distribution, the
population standard deviation, the standard deviation required to meet the 1.33 value (for
comparison), and the Cpk calculated using the population standard deviation. Table 11
contains the results including those of the underlying normal distributions, nAtT and
nAtO.
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Table 13

Results from Research Question 3
Population

Required

Standard

Standard

Distribution

mean

Deviation

Deviation

Cpk

nAtT

100.11

5.05

6.22

1.64

nAtO

95.11

5.05

5.03

1.64

gammaLowerT0

92.13

9.98

4.28

0.83

gammaUpperT0

107.64

9.98

4.34

0.83

gammaLowerT

93.18

8.91

4.55

0.93

gammaUpperT

106.64

8.97

4.59

0.92

gammaLowerO0

82.13

9.98

1.78

0.83

gammaUpperO0

112.64

9.98

3.09

0.83

gammaLowerO

86.15

7.13

2.79

1.16

gammaUpperO

110.39

8.19

3.65

1.01

lognormalLowerT0

92.45

3.04

4.36

2.73

lognormalUpperT0

107.55

3.04

4.36

2.73

lognormalLowerT

92.45

3.04

4.36

2.73

lognormalUpperT

107.55

3.04

4.36

2.73

lognormalLowerO0

82.45

3.04

1.86

2.73

lognormalUpperO0

107.55

3.04

4.36

2.73

lognormalLowerO

82.50

2.97

1.88

2.79

lognormalUpperO

107.55

3.04

4.36

2.73

weibUpperT0

108.72

10.42

4.07

0.80

weibLowerT

89.21

7.36

3.55

1.13

weibUpperT

106.73

8.39

4.57

0.99
(continued)
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Population

Required

Standard

Standard

Distribution

mean

Deviation

Deviation

Cpk

weibLowerO0

76.03

10.42

0.26

0.80

weibUpperO0

108.72

10.42

4.07

0.80

weibLowerO

83.12

5.20

2.03

1.60

weibUpperO

106.90

8.39

4.52

0.99

weibLowerT0

86.03

10.42

2.76

0.80

As expected, the underlying normal distributions exceeded the Cpk value of 1.33.
Only the distribution based on the upper offset Weibull distribution, and those based on
the lognormal distribution also exceeded the desired Cpk value of 1.33. The results from
this research question and Research Question 2 require joint analysis because of the
relationships between the data.

Summary
The purpose of this study was to develop a framework that evaluates the ability of

Cpk to accurately measure medical device test data under a scenario where output data
combines the effects of mixed production lots of components. Simulation with the R
(2016) programing language generated 12 different fat tailed distributions. These
distributions represented the test results of some product characteristic related to the
performance or safety of a medical device. I formulated three different research questions
to evaluate the performance of Cpk as a measure of process capability under the fat tailed
distribution scenario.
The first research question examined the overall performance of Cpk as a tool to
evaluate these processes. The analysis provided mixed results for this question. In 46% of
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the cases, the null hypothesis that the Cpk value met or exceed the desired 1.33 value was
not rejectable. In the other 54%, it was.
The second research question complimented the first. It provided a count of the
number of data points, as a number and as a percentage, that laid outside of the
boundaries needed for a Cpk of 1.33. Using separate methods for the count and the
percentage calculation provided an additional level of validity for the results. The results
showed that no points were outside of these boundaries.
The third research question, also a compliment to Research Question 1, was to
compare the results of the calculated Cpk for each component distribution with the desired
value of 1.33. The outcome evidenced mixed results. Both underlying normal
distributions met the criterion as expected. One distribution, based on the Weibull lateral
distribution, met the criterion. All of the distributions based on lognormal lateral
distributions also met the criterion.
The results were more varied than expected at the outset of this research. Chapter
5 contains more analysis and further discussion of the results given in this chapter.
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Chapter 5: Discussion, Conclusions, and Recommendations
The purpose of this empirical quantitative study was to develop a framework that
evaluates the ability of a PCI to accurately measure medical device test data in a scenario
where output data combines the effects of mixed production lots of components. The
study was comparative in nature, involving an examination of the performance of the
most commonly used PCI, Cpk, using simulated process data by calculating precise
capabilities and then comparing these values with the results generated from nonnormal
data adjusted indices.
The reasons for conducting the study are the ongoing FDA and ISO requirements
to prove that processes to manufacture medical devices are under control. Often the tools
used to determine control are PCIs, primarily Cpk. This index depends on the normality of
the data under test, and statistically unsophisticated engineers may often use it in the
absence of normality and unknowingly accept inaccurate results. Kane (1986) warned
against this misuse in the article in which he first introduced this index.
The results of this study validated the concerns of Kane (1986) and Gunter
(1989a, 1989b, 1989c, 1989d) regarding the application of this index to nonnormal data.
Although the 12 different data sets generated through simulation for this study contained
no points outside of the upper or lower tolerance limits, the calculated Cpk values
generally failed to meet the industry standard of a value of 1.33 or greater. However,
proper interpretation of the values would lead to a good understanding of the output of
the process and the direction any corrective action should take. The research findings also
contribute to filling a significant gap in the literature regarding the application of PCIs to
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the medical device manufacturing field where mistakes can be life threatening if a
procedure relies on a potentially defective device.

Interpretation of Findings
The design of the research questions in this study reflects an attempt to leverage
the FDA requirement for lot traceability of the subcomponents used in the manufacture of
a medical device to possibly overcome the limitations that nonnormal test results might
impose on the ability of the capability index Cpk to monitor a medical device
manufacturing process. The three research questions complement each other. The
purpose of the first question was to determine the control status of several different
processes as indicated by the calculation of Cpk for the processes calculated for different
sample sizes. The goal of the second question was to evaluate the actual output from the
processes to determine if defective output resulted. The objective of the last question was
to evaluate the possibility that decomposing the output of a process by lot could yield a
more accurate determination of process capability.
The results of this research both confirm and extend earlier findings. In the article
introducing Cpk, Kane (1986) cautioned that a prerequisite for its application was
normality of data. An early criticism of PCIs (Gunter, 1989a, a989b, 1989c, 1989d) held
that this dependency on normality is a weakness of the technique. The results of this
study generally show the process as being out of control, judged by the Cpk values
calculated in the first research question, while the results of the second research question
show that no defective product results from the processes. Relying on Cpk in this instance
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could result in time consuming and expensive efforts to “fix” a process that is producing
good product.
The probability of this situation occurring is increased by the fact that almost all
of the distributions examined in this study would be accepted as normally distributed by
the Anderson Darling test commonly used in normality testing. This result could lead a
practitioner to believe that there was no problem with the data. Examination of the plots
in Appendix A, or of the kurtosis results in Table 4, could indicate the soundness of this
conclusion with the possible exception of combination distributions five, six, seven, and
eight. These distributions, constructed using lognormal lateral distributions, are
platykurtic.
An unexpected and potentially significant result of this research was that, in spite
of their kurtosis values, combination distributions five and six had the highest Cpk values
and are the only distributions that yielded a Cpk value higher than 1.33. Three of the four
distributions with a value greater than 1.33 came from combination distribution 5
composed of the underlying normal and the offset lognormal distributions centered at the
target of 100. Combination distribution 5 appears to exhibit some degree of bimodality, a
characteristic even more pronounced in combination distribution 6. The values of the
standard deviation distributed around two modes symmetrically distant from the mean
could contribute to this result.
The only two combination distributions that were nonnormal by the Anderson
Darling test, and nontransformable, had lognormal lateral distributions with sample sizes
of 59. Figure 13 illustrates Cpk values by distribution. Because of the range of values for

135
the calculated sample sizes, this analysis only includes the standard sample sizes of 10,
30, and 59. Including the calculated samples sizes that ranged from seven to 48 could
mask any pattern related to sample size.

Figure 13. Combination distributions sorted by Cpk values.
What is particularly disturbing is that these values come from the lognormal
lateral distributions. Ott (2000) noted that lognormal distributions often represent data

136
mixed from several distributions. This is the very problem this study addresses. Although
the data in the study came from simulation, these results indicate that if mixed data comes
from upstream processes, it may lead to deceptive results requiring that the steps in the
study need application throughout the process rather than just where a clear mixing of
lots occurs.
A significant finding follows from the theory of sampling and statistical quality
control (Deming, 1950/1966, 1960/1990; Ott, 2000; Shewhart, 1931/2015, 1939/1986) is
the critical importance of choosing an appropriate sample size when evaluating a process
using Cpk. Figure 14 illustrates how the value of Cpk decreases with sample size. The
panels in this plot have the Cpk values arranged from the smallest sample size, 10, on the
bottom, to the larges sample size, 59, on the top. The Cpk values all migrate from right to
left with increasing sample size.
This effect could be due to the presence of n - 1, the unbiased sample size, in the
denominator of the equation used to calculate the sample standard deviation. As the value
of n increases, the sample standard deviation would decrease. To balance this effect, the
sample size calculation, based on the “… smallest value that is still considered to be
practically significant …” (Mathews, 2010, p.16), assumes more importance.
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Figure 14. Cpk variation by sample size.
This research extends current theory in two different ways. First, other researchers
have previously examined the behavior of Cpk using distributions other than normal
distributions. English and Taylor (1993) used the triangular, uniform and truncated
exponential distributions. Rivera et al. (1995) used the gamma, lognormal, and Weibull
distributions. Tang and Than (1999) used the lognormal and Weibull distributions. Pal
(2005) used the generalized lambda distribution, and Liu and Chen (2006) used the beta,

138
gamma, and Weibull distributions. A thorough search of the research could find more
examples. This study considered the component distributions together rather than
separately as might be the case with mixing of production lots as might be the case in real
world production environments.
Another extension to theory came from research question three, with the different
distributions considered individually rather than in combination. The focus in this
research question was to look at the variance of the individual distributions. Other
researchers introduced penalties or other considerations in their modifications of Cpk for
missing target values. Kane’s (1986) original work addressed target values. Chan et al.
(1988a), and Taguchi (as cited in Boyles, 1991) followed this path. Pearn, Kotz, and
Johnson (1992) with their introduction of Cpm.
In spite of the focus on the target, there are actually two factors that determine the
value of Cpk, the interval between the mean and the closest specification limit, and the
standard deviation of the distribution of the samples. In some cases, the latter might be a
more appropriate place to focus quality improvement efforts than the former. While the
values of the Cpks calculated from the overall combination distributions generally failed
to meet the standards, the results from research question 3 indicated that many of the
variances were sufficient to meet the 1.33 standard with the component distributions
considered separately. In light of the results from Research Question 2, showing that no
defective output resulted from any of the processes, this might also be a significant
finding.
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Limitations of the Study
This study had many limitations. First, the study design incorporated a total of
four different, but specific, frequency distributions, an underlying normal distribution, a
gamma distribution, a lognormal distribution, and a Weibull distribution. When
considering the different parameters that define these distributions, it is obvious that there
is an infinite number of possible distributions. Any variation in the parameter set used in
R’s (2016) random number generator would result in different distributions and possible
different results. A practitioner applying the methods developed in this study would have
to replicate many of the study steps to generate results. The study did not, nor was it
intended to, generate a generalizable formula to evaluate process output.
Second, the overall symmetry of the combination distributions may have affected
the results of the Anderson Darling normality tests. The creation of fat tailed distributions
by doing this was by design to increase the likelihood of Anderson Darling failures. In
actuality, the symmetry created the opposite effect. Nonsymmetrical distributions may
have better suited this design goal.
Third, this study takes advantage of the lot traceability present in the manufacture
of medical devices. While this closes a gap in the literature, it also limits the applicability
of this study to industries where this condition is present, either formally, as is the case in
FDA regulated industries, or informally where management has made the decision to
incorporate such traceability on their own. Attempts to apply the methods used in this
study to situations where lot traceability is not present would be difficult or perhaps
impossible.
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Recommendations
Recommendations for further study begin with addressing the limitations
identified in the previous section. Rather than distributing the lateral distributions around
the target mean of the underlying normal distribution by identical distances on either side,
asymmetric placement represents an alternative. For example, if the left lateral
distribution is one standard deviation from the target, the right distribution offset could
equal two standard deviations.
With symmetric placement of the lateral distributions, the mean of the
combination distribution stays centered around the target value. Each point to the left of
the mean has a balancing value to the right of the mean. Consider the placement of the
right lateral distribution two standard deviations rightward while the left lateral
distribution remains offset left by only one standard deviation. Because of the lack of
balance of values around the target, the mean would also shift to the right.
Along with the mean shift, the standard deviation would also grow larger due to
the increase in dispersion around the mean. The interval between the mean and the UTL
would decrease. It could be valuable to quantify the effect of the shortened interval paired
with the larger standard deviation upon the value of Cpk. Would Cpk increase or decrease
monotonically, or does it reach a maximum or minimum and then reverse direction?
A more extreme extension to this approach is eliminating one of the lateral
distributions altogether. Again, the mean would shift in the direction of the lateral
distribution, and the standard deviation would increase. Like the previous case,
quantification and determining the characteristics of the effect would be interesting.
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Both lateral distributions in this study had values above and below the tolerance
limits trimmed. This represented a normal screening process of subcomponents occurring
before the process combining the components from different lots. The trimming operation
eliminated the more extreme values and decreased the value of Cpk compared to
untrimmed components. A further extension to this research would be eliminating the
trimming and measuring the effect this would have on the Cpk values. This approach
could also use the asymmetric placement of the lateral values described previously.
In this research, I used the gamma, lognormal, and Weibull distributions as the
lateral distributions. Other researchers have studied Cpk behavior using other distributions
than these, although never in combination like the current study did. A follow-on study
could substitute the triangular or uniform distributions (English & Taylor, 1993), the
Generalized Lambda Distribution (Pal, 2005), or the beta distribution (Hosseinifard et al.,
2009) for the lateral distributions used in this study. This could also use asymmetric
placement, or only one lateral distribution.
In all of the extensions so far, I assumed the presence of the underlying normal
distribution. How could the elimination of this distribution affect the results? For
example, if two lateral distributions based on the gamma were studied, one tailing right
by transformation, and the other naturally tailing right, would the effect be close enough
to a normal distribution that a valid value of Cpk would result?
One distribution that was absent from the literature is the Gumbel distribution
formulated to address extreme or rare cases (Gumbel, 1958/2004). While capability and
control are goals for production processes, exceptions do occur. Studying the effect of
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rare malfunctions in a process could be interesting. While rare, the effects from such an
event could be very serious.
This study, by design, focused on one PCI, Cpk, because of its acceptance as the
industry standard (Peña-Rodríguez, 2013). It is possible that one of the many other
indices, developed since the introduction of Cpk, but not yet widely accepted, could
provide more accurate results under this study’s parameters. Further research could
investigate the performance of these other indices under the original design or under one
of the alternatives proposed in this section.
The current study addressed fat tailed processes. A last branch from the current
study would examine the opposite situation, that is, thin or nonexistent tails. These often
arise from a lack of granularity in the measurement process and can be difficult to
interpret properly (Sleeper, 2007). Further research using the comparison of variance
techniques used in this study might furnish a method to better analyze these situations.

Implications
The implications of this study affect three segments of society, the individual
patient, the manufacturers of medical devices, and the regulatory agencies responsible for
insuring that only safe products enter the marketplace. The individual patient relies on the
knowledge and professionalism of medical device manufacturers when undergoing a
treatment regimen that requires the use of a medical device. Patients enter treatment
expecting to have to fight a disease or other medical condition and they rely on the
quality of the devices used by medical professionals to help them in this effort. The
results of this study could help insure that the patients receive treatment with devices that
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perform as expected by making the device manufacturers more aware of the potential
shortcomings or the tools they rely on to insure quality.
Manufacturers face a constant balancing act between cost, quality, and
availability. A perfect device for the treatment of a condition with absolute reliability
might be possible to make. But, if that device costs 5 million dollars to manufacture, and
takes 100 skilled workers a year to make each one, it probably is not viable as a product
(note that single use devices, unlike MRI machines or something similar that can help
many patients over a long period of time, are the topic of this discussion). In a large scale
production environment, manufacturers have come to rely on statistical methods to insure
meeting quality and cost objectives. The regulatory agencies impose these requirements.
Failing to meet these requirements can have serious consequences for both the patients
and the manufacturers.
In January of 2017, the Department of Justice announced that Baxter Healthcare
had agreed to pay more than $18 million to resolve issues that arose from its failure to
follow Good Manufacturing Practices in one of its plants (U.S. Department of Justice,
2017). That sum paid to the government represents money that will not be invested in
research and development, plant expansion, or passed on to medical facilities or
stockholders. In addition, it is highly likely that the cost of this fine will eventually fall on
the healthcare consumers, contributing to ever increasing healthcare costs. While this
case involved pharmaceuticals rather than devices, it nevertheless indicates the possible
consequences companies face for failing to control their processes.
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By pointing out the weakness of a commonly used index, this study could help
healthcare companies, and their engineers, better understand the implications of reading
too much into the results of the applications of theses indices. It is not enough to apply a
formula to results without a good understanding of the data to which the index is applied.
Such understanding requires meaningful training.
Disseminating knowledge that one index alone cannot provide all of the needed
answers regarding process capability could be an important outcome of this research.
Additionally, a requirement that engineers in the medical industry have enough statistical
training to ask the right questions and to know when to seek expert help when confronted
with a situation beyond their statistical ability. Regulatory and standards organizations
impose many requirements on medical manufacturers. Recognizing and requiring
statistical literacy from those responsible for medical devices could be a worthy addition
to those requirements.

Conclusions
From the beginning, practitioners and theoreticians knew the weaknesses of PCIs
in dealing with nonnormal data. This study provided another verification of that
weakness, but also extended that finding to more complicated cases consisting of
multiple distributions combined into one. Perhaps the most significant finding of this
study is that a low value of Cpk did not necessarily indicate the production of failing
product. Had the data generated for this study represented an actual production situation,
misinterpretation of the low values of Cpk could have prevented the release of a new
product while the engineers fixed a product that met specifications.

145
Related to this was the performance of the Anderson Darling test statistic to detect
nonnormality in fat tailed distributions. A conscientious, but statistically unsophisticated,
engineer might accept the results of this test without question or further examination of
the data. The conclusion could be that the process is under control when it exhibits an
undesirable degree of spread.
I began this study with the hope of simplifying the use of Cpk to evaluate process
capability by decomposing distributions by lot identity. Based on the conclusions of this
study, it is apparent that a single capability index is unreliable when used alone to judge
if a process is capable. Instead, the index must be part of a system that combines both
statistical tools, for example, other tests for normality, variance comparison methods, and
so forth, and intimate process knowledge to evaluate the output of a process. Until that
occurs, overall process capability will still be difficult to evaluate properly.
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Appendix A: Histograms of Combination Distributions

Figure A1. Underlying normal distributions.
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Figure A2. Combination distributions formed with centered gamma distributions.
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Figure A3. Combination distributions formed with offset gamma distributions.
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Figure A4. Combination distributions formed with centered lognormal distributions.
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Figure A5. Combination distributions formed with offset lognormal distributions.
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Figure A6. Combination distributions formed with centered Weibull distributions.
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Figure A7. Combination distributions formed with centered Weibull distributions.
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Appendix B: R Code
The embedded object on this page contains the R code used to create the figures
used and do the analysis described in this study.

KwiecienJW_R_Cod
e_02262017.docx

I will also place the R code on GitHub at https://github.com/JimKw1091/JWKDissert.git.

